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Antibiotic Drug Discovery Targeting Bacterial Metabolism
Abstract
Over the last century, the use of antibiotics has enabled many advances in modern medicine, making life
as we know it possible. In recent years, however, emerging bacterial resistance to virtually all major
antibiotic classes has resulted in a worldwide increase in morbidity, mortality, and financial burden
associated with drug resistant infections. The antimicrobial resistance crisis presents an urgent need for
new antimicrobials with distinct mechanisms of action from existing drugs. The current pharmaceutical
pipeline of new antibiotics is limited due to three obstacles: a lack of understanding of resistance
mechanisms, a dearth of novel mechanisms of action among new antibiotics, and drug discovery
challenges unique to bacteria due to their cellular and physiological composition. My dissertation
research addressed each of these challenges. The mechanisms of resistance to folate biosynthesis
inhibitors in Staphylococcus aureus were explored from a genetic, biological, biochemical, and structural
basis. Unexpected roles in resistance and fitness were attributed to various mutations in the sulfonamide
target dihydropteroate synthase. This information currently guides the development of next-generation
antifolates designed to avoid these characterized resistance strategies. In the subsequent chapter, a
conditional metabolic screening approach was employed to discover inhibitors disrupting metabolic
pathways related to folate biosynthesis. The testing conditions were optimized to measure the biological
activity of antimetabolites, which is often masked by nutrients present in standard testing media. This
screen yielded an inhibitor of cysteine synthase A in Escherichia coli, which was characterized in chapter
four. Multiple experimental approaches yielded indications that the cysteine synthase A inhibitors have a
false-product mechanism, resulting in a widespread impact on several key branches of metabolism
beyond cysteine biosynthesis. The final research chapter describes the adaptation of the cellular thermal
shift assay to explore target engagement in the Gram-negative cell system. Drug entry and accumulation
are especially challenging to achieve in Gram-negative cells due to their unique dual membrane system
and associated efflux machinery. This assay provided an early stage tool to quickly assess the ability of
antimicrobial candidates to engage the intended target in the intact cell system and also measure efflux
sensitivity. Taken together, this dissertation contributes to the fight against the antimicrobial resistance
crisis from multiple angles, all within the context of bacterial metabolism which is a rich source of
exciting new antibiotic targets.
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ABSTRACT
Over the last century, the use of antibiotics has enabled many advances in modern
medicine, making life as we know it possible. In recent years, however, emerging
bacterial resistance to virtually all major antibiotic classes has resulted in a worldwide
increase in morbidity, mortality, and financial burden associated with drug resistant
infections. The antimicrobial resistance crisis presents an urgent need for new
antimicrobials with distinct mechanisms of action from existing drugs. The current
pharmaceutical pipeline of new antibiotics is limited due to three obstacles: a lack of
understanding of resistance mechanisms, a dearth of novel mechanisms of action among
new antibiotics, and drug discovery challenges unique to bacteria due to their cellular and
physiological composition. My dissertation research addressed each of these challenges.
The mechanisms of resistance to folate biosynthesis inhibitors in Staphylococcus aureus
were explored from a genetic, biological, biochemical, and structural basis. Unexpected
roles in resistance and fitness were attributed to various mutations in the sulfonamide
target dihydropteroate synthase. This information currently guides the development of
next-generation antifolates designed to avoid these characterized resistance strategies. In
the subsequent chapter, a conditional metabolic screening approach was employed to
discover inhibitors disrupting metabolic pathways related to folate biosynthesis. The
testing conditions were optimized to measure the biological activity of antimetabolites,
which is often masked by nutrients present in standard testing media. This screen yielded
an inhibitor of cysteine synthase A in Escherichia coli, which was characterized in
chapter four. Multiple experimental approaches yielded indications that the cysteine
synthase A inhibitors have a false-product mechanism, resulting in a widespread impact
on several key branches of metabolism beyond cysteine biosynthesis. The final research
chapter describes the adaptation of the cellular thermal shift assay to explore target
engagement in the Gram-negative cell system. Drug entry and accumulation are
especially challenging to achieve in Gram-negative cells due to their unique dual
membrane system and associated efflux machinery. This assay provided an early stage
tool to quickly assess the ability of antimicrobial candidates to engage the intended target
in the intact cell system and also measure efflux sensitivity. Taken together, this
dissertation contributes to the fight against the antimicrobial resistance crisis from
multiple angles, all within the context of bacterial metabolism which is a rich source of
exciting new antibiotic targets.
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CHAPTER 1.

INTRODUCTION

Discovery and Establishment of Antimicrobials in Modern Medicine
Penicillin is often regarded as the first antibiotic discovered in the modern era. In
1928 an agar plate in the laboratory of Alexander Fleming was serendipitously
contaminated with a Penicillium mold species that inhibited the growth of the pathogenic
Staphylococci originally inoculated on the plate (Fleming 1929). Penicillin was
eventually isolated and identified as the growth inhibitory component produced by the
mold by Ernst Chain and Howard Florey (Chain 1940). In the early 1940s, penicillin
proved to be an effective treatment for human infections and does in fact represent the
earliest antibiotic derived from a natural product (Abraham 1941).
Before the discovery of penicillin, however, two very important antimicrobial
chemotherapies had already been identified and deployed for treatment of human
infections. The earliest of these discoveries was arsphenamine, which represents the first
effective syphilis treatment (Williams 2009). Arsphenamine was originally synthesized
by Alfred Bertheim and found to be effective against spirochetes by Paul Ehrlich and his
assistants (Strebhardt 2008). This compound showed efficacy in clearing human syphilis
infections as early as 1909 and would become the standard of care for syphilis treatment
until penicillin was widely available in the 1940s (Williams 2009).
Another antimicrobial discovered before penicillin was prontosil, which was
originally synthesized as a dye in 1909 at the University of Vienna. It wasn’t until 1932
that this agent was found by Gerhard Domagk to clear Streptococcus pyogenes infections
in mice. Shortly after this discovery, prontosil showed promise in treating human
infections as early as 1935 (Chain 1940). It was later discovered that a colorless
component of the prontosil molecule, sulfanilamide, was active on its own (Trefouel
1935). Prontosil is metabolized in vivo to produce the active sulfanilamide component
(Mitscher 1995). Several sulfonamide derivatives have been generated since the
discovery of sulfanilamide, and this antibiotic class proved invaluable for war wounds
and systemic infections (Sköld 2000). Sulfonamides remain a cornerstone treatment
option for a variety of infection types today.
These early discoveries of arsphenamine, prontosil and penicillin spurred the
“Golden Age” of antibiotic drug discovery, which would last through the 1970s (Figure
1-1). Empirical screening efforts yielded numerous natural product-derived antibiotics
including β-lactams, aminoglycosides macrolides, tetracyclines, ansamycins, and
glycopeptides. Synthetic antibiotics were also generated, including nitrofurans, isoniazid,
and trimethoprim (TMP) (Silver 2011). This antimicrobial armamentarium developed
since the early 1900s has enabled the development of modern medicine as we know it
and has vastly improved global human health. Antimicrobials allow for improved
management of simple infections and communicable disease. Advanced medical
procedures and treatment regimens including chemotherapy, surgeries, and dialysis,
which render patients more vulnerable to infections, could be developed successfully
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Figure 1-1
Timeline of deployment of major antibiotic classes and the general cell
processes targeted.
Major antibiotic classes are color-coded according to their general cell target.
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with the help of antimicrobial therapies (Ventola 2015).
The Rise of Antibiotic Resistance
The deployment of new antibiotic classes to clinical use has slowed since the
1970s, although a few notable narrow spectrum agents have been introduced in recent
years (Figure 1-1) (Silver 2011, Lewis 2017). This decline in antibiotic discovery has
been concurrent with an increase in resistant infections in recent decades, resulting in a
global antimicrobial resistance (AMR) crisis. AMR is presently one of the largest global
health threats in the 21st century and imposes a high societal burden in terms of
morbidity, mortality, and financial loss. Approximately 2 million cases of AMR
infections occur annually in the United States resulting in 23,000 AMR-associated deaths
each year (Centers for Disease Control and Prevention 2013). It is estimated that without
significant intervention, the global death rate attributed to AMR could reach 10 million
deaths per year by 2050 and surpass death rates attributed to cancer (O’Neill 2016). An
alarming phenomenon is the increasing resistance rates observed against “last-resort”
antibiotic treatment options such as carbapenems and colistin among Gram-negative
(GN) pathogens (Tacconelli 2018). The resistance increasingly observed against
virtually every antibiotic class has introduced the possibility of entering a “post-antibiotic
era,” wherein antibiotic therapy is rendered ineffective and much of the progress made
with modern medicine over the last century is reversed (Alanis 2005).
Several factors have contributed to the current AMR crisis. An increasingly
“global” lifestyle wherein trade and travel are more commonplace has accommodated the
spread of resistant microbes. Antibiotic overuse in agriculture and aquaculture has
allowed for the introduction of antibiotics into the environment which encourages an
environmental reservoir of resistance genes. Antibiotics are often overprescribed in the
clinic and underregulated in developing countries, resulting in more frequent and
unnecessary use in humans. This overuse of antibiotics encourages resistance in both
community and hospital settings (Ventola 2015).
In response to antibiotic stress encountered in vivo or in the environment,
microorganisms readily employ numerous resistance mechanisms including target
modification, drug deactivation, efflux, and metabolic bypass of the antibiotic target.
AMR can be attributed to both resistance mechanisms evolved in direct response to
antibiotic exposure, or to inherent resistance mechanisms (Wright 2010). Resistance
genes are oftentimes rapidly disseminated in microbial populations through both vertical
transfer to daughter cells and horizontal transfer of plasmids. Subsets of microbial
populations can assume a “persister” state, wherein they assume a dormant state and are
highly tolerant to antibiotics within chronic infection types and biofilms (Lewis 2010).
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Strategies to Overcome Resistance
To effectively manage the global health crisis of AMR, improvements must be
made towards the ability to understand, monitor, and treat AMR infections. Surveillance
of AMR pathogens and resistance genes in the clinic, the community, and the
environment is critical for the detection, containment, and prevention of resistant isolates
(Tacconelli 2018). Emerging rapid diagnostics technologies yield significant promise
towards fast and accurate detection of the pathogenic species to allow for more targeted
and prudent antimicrobial treatment regimens. Reducing the use of antibiotics in
agriculture and aquaculture as well as higher regulation on antibiotic production and use
outside the clinic in developing countries would certainly reduce the development and
dissemination of AMR (Wright 2010).
A remaining strategy to overcome AMR that is addressed in this dissertation is to
develop desperately needed new and effective antibiotic therapies. The pharmaceutical
pipeline for new antibiotics has presented a strikingly low output of new antimicrobial
classes since the 1970s (Figure 1-1). Although three new antibiotic classes have been
introduced in the past couple of decades (streptogramins, oxazolidinones, and
lipopeptides), these agents are narrow spectrum (Lewis 2017). New and effective
antimicrobials for GN species are desperately needed in light of the rapid emergence of
resistance to antibiotics of “last resort.” Campaigns to develop new antimicrobial agents,
whether they are designed to target established or new antibiotic targets, need to be
developed with avoidance of known resistance mechanisms in mind.
Another issue with the existing antibiotic arsenal and even the ongoing
pharmaceutical pipeline is that these agents generally target a discrete set of general cell
processes including the bacterial cell wall, protein biosynthesis, and DNA biosynthesis
(Figure 1-1). Bacterial metabolism remains an underexploited avenue for antibiotic
development that has yet to be fully explored (Zlitni 2013). Although microorganisms
and humans often share the same metabolic requirements for basic cell functions,
microbes are evolutionarily distinct from mammals and often have unique biosynthetic
routes to obtain necessary metabolites. Several enzymes within these pathways are
structurally distinct or entirely absent in human systems, presenting them as ideal
candidates for drug development with a low likelihood of interaction with homologous
host targets. Antifolates are an existing antibiotic class which takes advantage of
differences in folate metabolism between microbes and humans (Bermingham 2002).
Other metabolic pathways are being investigated for similar antimetabolite mechanisms
of action (Zlitni 2013).
Folate Biosynthesis Is an Effective Target for Existing and Experimental
Antimicrobials
The folate biosynthetic pathway (FBP) plays a central role in the biosynthesis of
several metabolites necessary for basic cell function and survival. The final product of
this pathway is tetrahydrofolate (THF), which can act as a one-carbon donor during the
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biosynthesis of purines, thymine, and methionine. Furthermore, THF can act as a onecarbon acceptor in various degradation pathways (Bermingham 2002). THF and its
derivatives play key roles in both the one-carbon cycle and the folate cycle.
The first committed step of the pathway is the conversion of GTP to a pterin ring
which is catalyzed by GTP cyclohydrolase (Bermingham 2002) (Figure 1-2). This is
followed by three enzymes catalyzing kinase, aldolase, and pyrophosphokinase reactions
to form 6-hydroxymethyl-7,8-dihydropterin pyrophosphate (DHPP). Dihydropteroate
synthase (DHPS) forms 7,8-dihydropteroate from DHPP and para-aminobenzoic acid
(pABA), which is a product of the chorismate pathway (Dosselaere 2001). Glutamate is
added to the dihydropteroate, forming dihydrofolate. The final enzyme, dihydrofolate
reductase (DHFR), converts dihydrofolate to THF (Figure 1-2). The first four enzymes
in the pathway, ending with DHPS, are absent in mammals. Mammals obtain folates
from their diet, and therefore lack the upstream enzymes of this pathway. Many
microorganisms rely on the de novo biosynthesis of THF and lack the associated folate
uptake machinery.
Antifolates have held immense utility as broad-spectrum antibiotics for over 80
years (Domagk 1935). Antifolate antimicrobials target the upstream enzyme DHPS,
which is absent in humans, as well as DHFR. DHFR is present in both humans and
prokaryotes, however the antibiotic TMP has a much greater affinity for the bacterial
enzyme (Brogden 1982). A commonly prescribed antimicrobial antifolate therapy is cotrimoxazole, which is a combination of sulfamethoxazole (SMX) and TMP which targets
DHPS and DHFR, respectively. The two drugs show high synergy in combination and
are effective against a broad spectrum of microbial species. Co-trimoxazole is commonly
prescribed for urinary tract infections, ear infections, bronchitis, and pneumonia caused
by Pneumocystis jirovecii (Bermingham 2002).
There are various other antifolate antibiotics in addition to the co-trimoxazole
combination. Several sulfonamide derivatives have been generated since the discovery of
sulfanilamide with improved efficacy and reduced host toxicity (Mitscher 1995). A key
treatment option for multidrug resistant tuberculosis is para-amino salicylic acid (PAS)
which acts as a prodrug activated by DHPS and ultimately inhibiting DHFR (Zheng
2013). Dapsone is another DHPS inhibitor that acts as a second-line treatment for
Pneumocystis pneumonia and leprosy (Hughes 1998).
As with other antibiotic classes, resistance has compromised the utility of
antifolates, causing many of these agents to be relegated to second-line treatment options.
Resistance to sulfonamides and TMP is primarily achieved through target modification
among Gram-positive (GP) and Plasmodium species (Sköld 2000). GN bacteria are
notorious for gaining antifolate resistance through resistance plasmids encoding a
resistant variant of either DHPS or DHFR, or through overexpression of the DHFR
enzyme (Palmer 2014). Despite these observed resistance mechanisms, the immense
clinical and historical utility of the FBP as an antimicrobial target has inspired several
ongoing campaigns to develop next-generation antifolate inhibitors with the goal of
avoiding known resistance mechanisms (Bermingham 2002).
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Figure 1-2. The folate biosynthesis pathway.
Dihydropteroate synthase; PPi = Pyrophosphate; FPGS = Folypolyglutamate synthase;
DHFR = Dihydrofolate reductase.
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Antibiotic Discovery Towards Cysteine Biosynthesis
In addition to the FBP, cysteine biosynthesis is another metabolic branch that is of
interest for antibiotic discovery. Cysteine is one of the 20 proteinogenic amino acids and
has several essential biological roles. The thiol groups between two cysteines on
disparate regions in the primary amino acid chain can form a disulfide bond, contributing
to important aspects of the tertiary structure of proteins. Cysteine residues play important
roles in metal cofactor binding in several enzymes (Beinhert 2000, Kessler 2006). In
prokaryotes, a key branch point occurs between the reductive sulfate assimilation
pathway (RSAP) and cysteine biosynthesis, and as a result cysteine is a precursor for
sulfur-containing molecules involved in redox homeostasis and anti-oxidative defense,
including glutathione, mycothione, and trypanothione (Schnell 2015) (Figure 1-3).
Similar to the early stages of folate biosynthesis, cysteine biosynthesis in bacteria
is unique from mammalian systems. Prokaryotic cysteine biosynthesis occurs in two
distinct steps (Kredich 1966) (Figure 1-3). Serine acetyl transferase (SAT) catalyzes the
first step, wherein OALS is synthesized from L-serine and acetyl CoA. In the second
step, cysteine synthase A (CysK) produces L-cysteine from OALS and sulfide. In many
bacterial species, the isoenzyme cysteine synthase B (CysM) is present but understood to
only be active in anaerobic conditions (Kredich 1996).
The C-terminal tail of SAT inhibits the CysK active site in the absence of
adequate pools of OALS (Huang 2005). Various inhibitor series have emerged that
mimic the inhibitory interactions of SAT with the CysK enzyme (Campanini 2005, Salsi
2010). Isozyme-specific inhibitors of CysK and CysM from S. typhimurium have been
discovered through virtual screening (Spyrakis 2013). Other inhibitor series targeting
CysK have been developed for the treatment of Mycobacterium tuberculosis (Jean Kumar
2013, Poyraz 2013), Trichomoniasis vaginalis (Singh 2013, Westrop 2006) and
Haemophilus influenzae (Salsi 2010, Amori 2012). Natural product derived
naphthoquinone compounds inhibiting CysK have been discovered with amoebicidal
activity against Entamoeba histolytica (Mori 2015).
Rather than inhibit CysK directly, an alternative mode of action against CysK was
presented by Kredich and coauthors in the 1970s. It was found that the growth of S.
typhimurium could be inhibited by formation of a false product mediated by CysK
between 1,2,4-triazole and OALS (Kredich 1975). This led to dysregulation of the
transcription of genes related to sulfur metabolism. This inhibitory mechanism does not
appear to have been revisited since.
Drug Discovery Challenges Unique to GN Bacteria
A puzzling phenomenon occurring since the Golden Age of antibiotic discovery is
the fact that antimicrobial drug discovery has waned despite incredible scientific
advances in genetics, structural biology, and high throughput screening (HTS) (Silver
2011). The scientific literature from the past few decades is replete with exciting new
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Figure 1-3. Cysteine biosynthesis and associated pathways in prokaryotes and
mammals.
Blue lines represent metabolic processes unique to prokaryotes and lower eukaryotes,
while red lines represent metabolic processes unique to higher eukaryotes.
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inhibitor series engaging novel bacterial targets, yet very few make it to the clinic. A
great deal of time and resources are often devoted to the in vitro characterization and
development of new inhibitor series, but these compounds perform poorly when
introduced to whole cell assays. Formidable barriers to achieving biological activity are
poor penetration of the bacterial cell membrane as well as limited residence time due to
efflux and target modification (Figure 1-4). The unique physiological properties and
sophisticated resistance mechanisms of the bacterial cell contribute to the high attrition
rate associated with the anti-infective drug discovery process. The medicinal chemistry
requirements for effective antibiotic drug design does not reliably follow parameters such
as Lipinski’s rule of five that have been useful for drug development against human
targets (Lewis 2013).
The majority of the most concerning pathogenic species contributing to the
current AMR crisis are GN bacteria, which are especially difficult to drug (Brown 2014,
Silver 2016). GN bacteria have an additional outer membrane which distinguishes them
from GP bacteria and further limits the entry of molecules with diverse physiochemical
properties. If a molecule finds its way across the outer membrane, it must traverse the
periplasmic space, penetrate the cytoplasmic membrane, and reside in the cytoplasm long
enough to exert its intended antimicrobial effect. Molecules are susceptible to efflux and
modification in both the periplasmic and cytoplasmic space (Figure 1-4). GN bacteria
are especially notorious for their ability to efficiently efflux several antibiotic classes,
limiting the residence time and efficacy of the drug (Silver 2016). Methods to gauge and
refine the ability of early stage inhibitors to perform optimally in the GN cell system are
certainly needed to reduce the high attrition rates observed in early stage inhibitor
development.
Improving Antibiotic Drug Discovery by Engaging Critical Metabolic Pathways
Microorganisms are evolutionarily distinct from humans. From a cellular
perspective, humans and microbes share similar requirements for basic cell metabolism.
Prokaryotes and lower eukaryotes, however, have developed unique metabolic pathways
to accommodate rapid changes in their environment, such as during the establishment of
an infection. Higher eukaryotes have formed a reliance on their diet and commensal
microbes to obtain essential metabolites. These factors have resulted in vast distinctions
between humans and pathogenic microbes in terms of available biosynthetic machinery
and metabolic requirements, suggesting bacterial metabolism as a promising avenue for
antibiotic drug discovery and development. For these reasons, this dissertation examines
bacterial metabolism as a source of potentially life-saving therapies with a focus on
improving current methods in antibiotic drug discovery.
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Figure 1-4. The Gram-negative cell membrane system.
The dual membrane system, efflux machinery, and modifying enzymes within the
periplasm and cytoplasm can all have negative effects on drug entry and accumulation.
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CHAPTER 2.

ANALYSIS OF CHROMOSOMAL RESISTANCE MUTATIONS
IN STAPHYLOCOCCUS AUREUS1
Introduction

Sulfonamide resistance in S. aureus and other clinically relevant species
Sulfonamides are a cornerstone treatment option for a wide range of infection
types and have had clinical utility for over 80 years. However, resistance to sulfonamides
was observed very quickly after its discovery and is still reported (Domagk 1935,
Bermingham 2000). Although the co-trimoxazole combination with TMP reduces the
likelihood of resistance, global resistance to both SMX and TMP is increasingly observed
and is a significant clinical issue today (Sköld 2000).
Resistance to sulfonamides can arise by a variety of mechanisms among
pathogens. Several species including S. aureus, E. coli, Streptococcus pneumoniae,
Plasmodium spp., and Pneumocystis spp. obtain sulfonamide resistance through
chromosomal mutations in the target enzyme DHPS (Sköld 2000). Increased production
of pABA has also been observed in resistant strains of S. aureus, which has been shown
in various studies to antagonize the growth inhibitory action of sulfonamides (Landy
1943, Zlitni 2013). GN enteric pathogens including E. coli, Klebsiella pneumoniae, and
S. typhimurium acquire sulfonamide resistance horizontally through dissemination of sul
genes 1, 2, and 3 which encode resistant DHPS isoenzymes (Toleman 2007).
Sulfonamide resistance in S. aureus is a particularly pressing issue due to the
recent epidemic of MRSA infections, for which antifolates are a key second-line
treatment option when other regimens fail (Zetola 2005). Globally, staphylococcal
species are more frequently exhibiting resistance to multiple antibiotic therapies
including vancomycin, daptomycin, and linezolid (Tacconelli 2018). Although cotrimoxazole is often relegated to the status of a second-line treatment option, it remains a
valuable, cheap and effective regimen for multiple infection types caused by drug
resistant staphylococci including skin and soft tissue infections and sepsis (Bowen 2017,
Goldberg 2010). Therefore, antifolate resistance in staphylococcal species is a major
concern due to the fact that these therapies serve as crucial treatment options, especially
when frontline drugs fail.

1

Modified from final submission with open-access permission. Griffith EC, Wallace MJ, Wu Y, Kumar G,
Gajewski S, Jackson P, et al. The structural and functional basis for recurring sulfa drug resistance
mutations in Staphylococcus aureus dihydropteroate synthase. Front Microbiol. 2018 Jul 17;9:1369.
[doi:10.3389/fmicb.2018.01369]
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Improved understanding of DHPS structure and function in recent decades
Given the immense clinical utility of sulfonamides and their efficacy against S.
aureus, next-generation DHPS inhibitors that are both effective against S. aureus and
recalcitrant to known sulfonamide resistance mechanisms are highly desired Bermingham
2000). Effective drug development regimes benefit from a comprehensive understanding
of the structure and function of the inhibitor target. Fortunately, several studies over the
last couple of decades have vastly improved the understanding of the DHPS structure and
catalytic mechanism as well as the overall FBP. The structures of DHPS have been
reported for several pathogenic species including S. aureus (Hampele 1997), B. anthracis
(Babaoglu 2004), Yersinia pestis (Yun 2012), S. pneumoniae (Levy 2008), Francisella
tularensis (Shaw 2014), and M. tuberculosis (Baca 2000). DHPS is a dimeric (β/α) TIMbarrel enzyme with the active site situated at the C-terminal end of the barrel (Figure 21A). The active site consists of three regions: A structured pterin binding site deep
within the TIM barrel, an anion binding pocket occupied by the DHPP leaving group
pyrophosphate (PPi), and a set of flexible loops at the C-terminal edge of the enzyme
where both pABA and sulfonamides bind. Sulfonamides are structural mimetics of the
native substrate pABA. They bind in the same flexible loop region and undergo DHPSmediated catalysis to form a metabolically useless false product with DHPP (Palmer
2014).
DHPS native catalysis was originally hypothesized to occur by a SN2 mechanism
(Baca 2000), but more recent studies indicate the reaction is more likely a SN1 reaction,
wherein a cationic intermediate is formed by release of PPi before the nucleophilic attack
of pABA on the DHP+ intermediate, forming the 7,8-dihydropteroate product (Yun
2012) (Figure 2-1B). The pABA/sulfonamide binding site at the C-terminal edge of the
DHPS enzyme is composed of a disordered flexible loop system that has proven difficult
for structural characterization. A 2012 study on Y. pestis DHPS successfully captured the
conformations of loops 1 and 2 which form a substructure during native catalysis
necessary to form the pABA binding pocket (Yun 2012). These two loops are well
conserved among multiple species and sulfonamide resistance mutations are commonly
observed in this region among several pathogenic species (Babaoglu 2004). The same
study on Y. pestis DHPS also revealed functional roles for the magnesium cofactor in
aiding the release of PPi and helping to order the loop 1-2 substructure (Yun 2012).
Recent structural and functional characterizations have also revealed potential
new sites for inhibitor binding in addition to the traditional sulfonamide binding site
which is amenable to mutation. Allosteric inhibitors that bind the DHPS dimer interface
have been discovered and characterized. These inhibitors prevent “breathing motions”
within the DHPS dimer that normally aid in substrate release from the enzyme and
influence the loop 1-2 active site structure (Hammoudeh 2014). The pterin binding
pocket has also been investigated as a potential site for inhibitor engagement.
Monocyclic pteridine analogs were developed by Burroughs Wellcome in the 1980s to
engage the pterin binding site of DHPS (Lever 1985). Structure-based technologies
allowed for improving the engagement of the pterin site with pyridazine inhibitors (Zhao
2012). This study also garnered an improved understanding of interactions of both native
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Figure 2-1. Structure and catalytic mechanism of DHPS.
A. DHPS transition state complex structure from PDB 3TYZ with three ligands bound
including the DHP+ cationic intermediate, PPi, and pABA. DHP+ and pABA are in grey
sticks, while PPi is in orange sticks. B. SN1 catalytic mechanism carried out by DHPS.
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substrate DHPP and inhibitors with conserved residues comprising this pterin binding
site.
Recent insights into the FBP function and candidacy for next-generation inhibitor
development
Folate biosynthesis is highly interconnected with diverse branches of bacterial
metabolism. Both the products and intermediates of this pathway have important roles in
other biosynthetic pathways and basic cell functions (Bermingham 2002). The pathway
begins with GTP, which is a purine nucleobase that is well known for its role as a
building block of RNA during transcription. The DHPS substrate pABA is derived from
chorismate, which is also a precursor for aromatic amino acids and other aromatic
metabolites (Dosselaere 2001). Folates and derivatives have established roles in both the
folate cycle and one-carbon metabolism, which is responsible for methylation reactions,
thymidylate biosynthesis, and the biosynthesis of glycine, serine, and methionine. THF is
also a precursor for inosine-monophosphate, pantothenate, and tRNAfmet in addition to
other important metabolites (Bermingham 2002).
Due to the interconnectedness of both the enzymes within the FBP and other
closely associated metabolic pathways, the synergy and efficacy of antifolates in
combination therapy is not surprising. For several decades, however, the detailed
mechanism of synergy between sulfonamides and TMP was not extensively delineated.
The fact that DHPS precludes DHFR in the pathway suggests that sulfonamides
potentiate TMP by limiting the DHFR substrate DHF, but the mechanism of potentiation
of sulfonamides by TMP was less obvious. A recent study identified a metabolic
feedback cycle between THF and DHPP. Knocking out enzymes within this loop
increased susceptibility to SMX (Minato 2018). This suggests a mechanism wherein
TMP potentiates SMX by limiting the production of inosine-monophosphate, which is a
precursor for GTP and consequently also a precursor for DHPP.
In recent years the role of pABA as both an antagonist of sulfonamides as well as
a potential new antibiotic target has been explored. The growth inhibitory actions of
various antibiotic classes are known to be antagonized by metabolites that are closely
related to the target protein, and supplementation with pABA has been shown to mask the
growth inhibitory action of sulfonamides (Zlitni 2013). Disrupting the biosynthesis of
pABA by small molecule inhibitors is an emerging area of interest in inhibiting the
growth of both E. coli and M. tuberculosis. Limiting pABA production has also been
shown to potentiate the effects of antifolates (Zlitni 2013, Thiede 2016).
The efficacy of antifolates is clearly due to the important roles assumed by folates
in several essential aspects of bacterial metabolism. This pathway remains an attractive
target for new inhibitor development, and DHPS is an excellent candidate for new drug
design due to improved understanding of both the structure and function of the enzyme as
well as potential new druggable sites (Bermingham 2002). To achieve effective inhibitor
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development, progress towards understanding resistance mechanisms from a structural
and functional standpoint is still required and is addressed within this chapter.
Materials and Methods
Genetic survey of available S. aureus DHPS sequences
The genetic survey of DHPS sequence variations from S. aureus was conducted in
2014. The DHPS WT sequence from Rosenbach 25923 was entered into a GenBank
BLAST search among the available genetic data for S. aureus. A set of 80 non-redundant
DHPS sequences and 56 reference strains were retrieved and compared to the WT DHPS
sequence. The sequences were categorized based on having a 25923 or 8325 background
as well as having known mutations associated with resistance.
Heterologous expression and purification of recombinant DHPS variants
The gene encoding folP from S. aureus 25923 (EMBL Z84573) and the genes
representing each mutation alone and in combination were codon optimized for
expression in the E. coli host and cloned into the pET16b vector with an N-terminal 10x
Histidine tag. The gene for folP from S. aureus 8325 was also cloned into pET16b in this
manner. All plasmids were transformed into E. coli BL21[DE3] cells. Transformants
that grew on the selective agent ampicillin were selected and sequenced to ensure
successful transformation.
For purification of the DHPS variants, an overnight culture of the transformed E.
coli was used to inoculate 4 liters of LB with ampicillin at at 50 μg/mL. Once the
cultures reached mid-log (OD600 between 0.4 and 0.7), IPTG was added to a final
concentration of 1 mM, and the cultures were allowed to incubate overnight at 18° C with
225 RPM shaking. The next day, the cultures were centrifuged at 3700xG for 10
minutes, the supernatants were removed, and the pellets were kept on ice. The buffers
used for lysis and purification were “Buffer A,” which contained 50 mM Tris-HCl, 500
mM NaCl, 5 mM imidazole, pH 8, and “Buffer B” which was the same except for having
500 mM imidazole. 50 mL buffer A with a protease inhibitor cocktail tablet (Roche 11836-170-001) and 500 mg lysozyme were used to resuspend each 1 liter pellet by
pipetting and vortexing. The lysates then underwent sonication at 3 minutes and 100%
amplitude three times. An additional 3 minutes was added to each sonication time for
each additional liter of bacteria. The lysates were then centrifuged at 20,000 RCF for 30
minutes at 4° C. The resulting supernatants were passed through a 0.22 μM filter.
The prepared lysates were loaded onto a GE HisTrap HP 5 mL column at 0.5
mL/minute to allow slow binding of the Histidine-tagged DHPS proteins onto the
column. Buffer A was allowed to wash the column for several column volumes to
remove background proteins. DHPS protein was then eluted in 1 mL fractions by a 0-
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100% Buffer B gradient over a span of two hours at 0.5 mL/min. Fractions with an
elevated UV spectra were analyzed by total protein staining after SDS-PAGE
electrophoresis to identify fractions with purified DHPS at the expected molecular
weight. Fractions containing DHPS were then pooled and run over a HiPrep 16/60
Sephacryl S-200 HR column at 0.5 mL/min in 50 mM HEPES, 150 mM NaCl, 1 mM
DTT, pH 7.6 and fractionated as before. The fractions were again analyzed by SDSPAGE electrophoresis. Fractions containing at least 95% pure DHPS were retained and
pooled. The protein was then flash-frozen in liquid Nitrogen and stored at -80° C for up
to six months.
Generation of isogenic S. aureus strains
The folP gene from S. aureus strain NCTC 8325 was ligated into the
PCR2.1TOPO plasmid. The eight mutants of this gene, including F17L, S18L, T51M,
E208K, KE257_dup, F17L E208K, F17L KE257_dup, and T51M E108K, were
introduced to the folP gene via site-directed mutagenesis. These genes were then
subcloned into the PJB38 vector, which has an S. aureus origin of replication that is
temperature sensitive. These plasmids were transformed into S. aureus USA300
AH1263. Transformants were allowed to grow in media containing CAM at 43° C to
allow for plasmid integration. The bacteria were then grown at 30° C and grown on
anhydrous tetracycline to allow for killing of cells that still retained the plasmid. The
successful transformants were further confirmed by sequencing of the chromosomal folP
gene and testing for susceptibility to CAM. Except for T51M E208K, all other mutants
were successfully cloned.
Minimum inhibitory concentration (MIC) determination
All MIC testing was performed in SSM9PR media, which is a minimal media
developed for S. aureus (Reed 2015). The drugs of interest were diluted two-fold across
96-well plates in a total volume of 100 μL per well. Colonies of each strain tested were
used to inoculate a small volume of SSM9PR media to a mid-log OD600 between 0.3 and
0.7. This culture was further diluted to an OD600 of 0.001. To each well of the drugged
MIC plate, 100 μL of the diluted culture was added, allowing for approximately 105 CFU
to be added per well. The plates were allowed to incubate at 37° C for 16 hours, after
which the MIC80 was determined visually. Each MIC reported is an average of three
biological replicates, which were each performed on different days.
Growth rate study
A single colony of each mutant was used to inoculate 5 mL LB broth and grown
overnight at 37° C, 225 RPM shaking. The next day, the cultures were diluted 1:100 and
the OD600 was read every 30 minutes. Using data from the exponential phase for each
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strain, the doubling times for each mutant was calculated following previously described
methods (Reeve 2016):
Wax moth larvae infection study
Galleria mellonella (wax moth) larvae in the final instar stage (Fisher Scientific
14-726-369) were stored at 13° C and used within a week of receipt. For each
experiment, all larvae came from the same batch. Each group contained 32 larvae, which
were stored in square bioassay dishes lined with filter paper. Control groups for each
experiment always included a group that was not manipulated as well as a group that was
only injected with the vehicle.
For the virulence and rescue studies, the inoculum was prepared by first
inoculating 5 mL of LB with a single colony of the strain tested. Once this culture
reached mid-log, it was washed with ice-cold PBS and further diluted 1:20 in ice-cold
PBS. Each larvae was administered an intrahaemocoelic injection with 10 μL of the
prepared inoculum, allowing for 5.9 x 105 CFU to be administered. The inoculums were
enumerated in triplicate to ensure appropriate and equal bacterial densities among all
strains tested. For the rescue experiments, 10 μL of SMX in a PBS/5% DMSO solution
was administered two hours before the infection and at 24 and 48 hours at a final
concentration of 100 mg/kg in each larvae. Larvae were monitored periodically to
determine mortality rates. Mortality was determined if both a lack of motility and change
in color were observed (Tsai 2016). To determine significant differences in mortality
rates among the groups tested, the Log-rank (Mantel-Cox) test was employed.
X-ray crystallography
Purified SaDHPS F17L E208K was equilibrated and concentrated to 20 mg/mL in
50 mM HEPES, 150 mM NaCl, and 1 mM DTT at pH 7.6. Crystallization optimization
trials yielded a favorable condition at 18°C of 0.2 M sodium nitrate, 25 mM HEPES, 75
mM NaCl, 20% PEG 3350, pH 7.6. For the co-crystal structure, 1530 was added at a 3:1
molar ratio with the enzyme and soaked for 16 hours. The soaked crystals were
combined with a cryoprotectant of 25% glycerol and flash-frozen. Data was collected
using the 22-ID X-ray beamline at the Southeast Regional Collaborative Access Team
(SER-CAT) at Argonne National Laboratory. XDS was used to index and integrate
diffraction images (Kabsch 2010). The images were further scaled and merged using
CCP aimless in the P43 space group. PHASER was used to solve the structure using
coordinates from SaDHPS PDB 1AD4 as a search model (Hampele 1997, McCoy 2007).
PHENIX was employed for reciprocal space refinement with NCS restraints, twin law h,k,-l, and TLS definitions within final cycles (Afonine 2012). To create ligand restraints,
eLBOW was employed (Moriarty 2009). COOT was used for real space refinement
(Emsley 2004). The structures have been deposited in the Protein Data Bank with the
accession codes 6CLU and 6CLV. Refinement statistics and data collection data are
previously reported (Griffith and Wallace, 2018).

17

Results and Discussion
Identification of five sulfonamide resistance mutations in S. aureus DHPS
Over the last couple of decades, improvements in sequencing and deposition of
genetic information on clinical isolates has provided ample information in GenBank to
identify variations in the folP gene of S. aureus, which encodes DHPS. 132 DHPS
sequences were identified in GenBank including sequences from 56 reference strains and
80 non-redundant DHPS sequences. Among these, 16 variations were present in the
DHPS enzyme (Table 2-1).
In a 1997 study by Hampele and coauthors, 15 of these variations were observed
among a collection of sulfonamide-resistant clinical isolates, leading the authors to
conclude the mechanism of DHPS resistance to be due to mutations in combination
(Hampele 1997). It was noted that both S. aureus Rosenbach 25923 and NCTC 8325 are
sulfonamide susceptible, and there are 11 variations between the two strains. Therefore,
these variations were considered natural polymorphisms or background mutations that
have no role in resistance (Table 2-1).
This left five mutations, F17L, S18L, T51M, E208K and KE257_dup. All of
these mutations apart from S18L were identified in the previous study on S. aureus
DHPS, and the isolates in that study exhibited high level sulfonamide resistance
(Hampele 1997). Furthermore, previous studies in our lab revealed that SMX-resistant S.
aureus harboring the S18L mutation could be obtained upon serially passaging wild-type
(WT) S. aureus in increasing concentrations of SMX (Griffith 2015). Genetic data from
both the available GenBank sequences and the Hampele et al. study revealed that F17L,
S18L, and T51M mutations could be observed by themselves while the E208K and
KE257_dup mutations were only observed in combination. This led to the categorization
of these mutations as primary and secondary, respectively (Tables 2-1 and 2-2).
Identification of homologous resistance mutations in other species
In addition to S. aureus, sulfonamide resistance is known to occur in several other
diverse species of microorganisms. Therefore, this study on resistance mutations in the
DHPS enzyme of S. aureus could also inform resistance mechanisms in other clinically
relevant species. Towards this end, the available literature on sulfonamide resistance was
surveyed. Mutations homologous to the identified sulfonamide resistance mutations in S.
aureus were discovered that originated either in in a lab setting or in clinical isolates that
were exposed to the drug in vivo (Table 2-3). The F17L mutation in loop 1 was identified
in E. coli (Dallas 1992), B. anthracis (Yun 2012), and Neisseria meningitidis (Fermer
1995). Mutations homologous to T51M in loop 2 were identified in S. pneumoniae
(Maskell 1997), Pneumocystis carinii, Plasmodium spp. (Mei 1998, Pornthanakasem
2016), and M. leprae (Kai 1999). Two Plasmodium species, P. falciparum and P. vivax,
also had a mutation homologous to the E208K secondary mutation (Pornthanakasem
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Table 2-1.

Categorization of DHPS amino acid variations identified in this study.
Mutation Type

Mutation
I30V, N31T, I37M, V58I, S59T,
L60V, M64L, M101I, I117V,
I126V, L266F

Backgrounda
Primary
Resistance

F17L, S18L, T51M

Secondary
Resistance

E208K, KE257_dupb

a

Background mutations are variations observed between the two sulfonamide-susceptible
S. aureus strains NCTC 8325 and Rosenbach 25923.
b
KE257_dup is a KE duplication insertion mutation at position 257.

Table 2-2.
Survey of DHPS sequence variations and reported sulfonamide
susceptibility.
Sequence
Background
Resistance
mutations
% Sequences
(n=136)
Hampele MIC
(µg/mL)a
Sulfonamide
resistant

25923

8325

8325

25923

8325

8325

25923

8325

25923

8325

None

None

F17L
KE257_dup

T51M
E208K

T51M
E208K

F17L
E208K

F17L

F17L

T51M

S18L

28

49

3

8

1.5

3.7

3

2

0.7

0.7

256 - >1024

256 >1024

>1024

>1024

Yes

Yes

Yes

Yes

ND

ND

ND

ND

No

No

a

Data source: MIC values from Hampele IC, D'Arcy A, Dale GE, Kostrewa D, Nielsen
J, Oefner C, et al. Structure and function of the dihydropteroate synthase from
Staphylococcus aureus. J Mol Biol. 1997 Apr 25;268(1):21-30.
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Table 2-3.
Occurrence of identified sulfonamide resistance mutations in other
pathogenic species.
Classification Mutation
Primary
F17L
S18L
Secondary

Location
Loop 1
Loop 1

T51M

Loop 2

E208K
KE257 dup

α-helix Loop 7
α-helix 8

ab

Similar Mutations in Other
Organisms
E. coli, N. meningitidis, B. anthracis
None
S. pneumoniaea, P. falciparuma, P.
vivaxa, M. leprae, P. carinii
P. falciparumb, P. vivaxb
None

, Indicates that T51M and E208K mutations align with observed mutations in these
species, but these mutations are not strictly conserved.
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2016). Mutations corresponding to S18L and KE257_dup were not identified in other
species.
An alignment was assembled to compare the DHPS primary sequences of S.
aureus and other pathogenic species (Figure 2-2). It was observed that amino acids
within loops 1 and 2 are highly conserved, and the observed primary mutations F17L,
S18L, and T51M reside within these highly conserved regions. The two secondary
mutations, E208K in α-helix loop 7 and KE257_dup at the dimer interface, are not
conserved among the various microbial species studied and thus appear to represent
sulfonamide resistance mutations unique to S. aureus.
In vitro characterization of DHPS enzymes harboring sulfonamide resistance
mutations
The location of primary mutations in conserved regions of the enzyme with
known roles in native catalysis indicates mutations may have consequences in terms of
biochemical function. The secondary mutations were never identified without the
presence of a primary mutation and occur on sites of the DHPS enzyme that are less
conserved without an immediately obvious role in enzymatic function. These
observations suggest that the secondary mutations may compensate for fitness costs
associated with the primary mutations which may affect the normal function of the
enzyme.
To gain a clearer understanding of the consequence of each mutation on
enzymatic function, nine total DHPS proteins harboring each mutation either singly or in
the observed clinical combination were expressed and purified in a heterologous E. coli
expression system. A series of biochemical experiments were performed using these
DHPS variants (Table 2-4). A colorimetric assay was used to obtain KM values for
SMX, pABA, and DHPP by tracking PPi that is released during the normal catalysis of
the enzyme. Furthermore, Ki values were obtained by an assay monitoring product
formation between 14C-labeled pABA and DHPP.
It was found that primary mutations had a high consequence to the binding
affinity for pABA in contrast to DHPP. However, secondary mutations modulated the
KM values for DHPP more so than pABA. This may be due to the proximity of primary
mutations to the pABA binding site, whilst secondary mutations are in more structurally
sound regions of the enzyme that may impact the pterin binding region which is deep in
the β-barrel. Mutations in combination consistently restored the pABA KM when
compared to primary mutations alone, suggesting the secondary mutations do indeed
have a compensatory effect (Table 2-4).
The two primary mutations F17L and S18L greatly increased both the binding
affinity and inhibition constant for SMX. Addition of E208K even further increased this
in vitro resistance. The impact of T51M on inhibition was less pronounced, even in
combination with E208K. Substrate turnover for both pABA and SMX was also
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Figure 2-2. Sequence comparison of DHPS from S. aureus and other key pathogenic species.
Blue shading indicates 100% amino acid conservation, light blue indicates high conservation, and grey indicates weak conservation.
The locations of identified resistance mutations are boxed in red.
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Table 2-4.

Biochemical profile of SaDHPS variant enzymes.

SaDHPS Variant
Mutation Type
Primary mutation

Secondary mutation
Double mutants

WT
F17L
S18L
T51M
E208K
KE257_dup
F17L E208K
T51M E208K
F17L KE257_dup

Native Substrate
KM DHPP
KM pABA
(µM)
(µM)
10.0 (±1.4)
3.1 (±0.9)
18.3 (±4.7)
40.2 (±6.1)
10.2 (±1.8)
26.2 (±0.2)
12.1 (±2.6) 29.8 (±13.2)
34.5 (±2.2)
15.7 (±4.5)
21.1 (±1.6)
5.3 (±3.0)
21.3 (±6.8)
13.1 (±2.6)
38.1 (±1.5)
9.2 (±3.5)
22.3 (±5.6)
14.3 (±3.3)
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SMX Antibiotic
KM SMX
Ki SMX
(µM)
(µM)
5.9 (±0.2)
1.3 (±0.5)
202 (±54)
94.1 (±23.7)
140 (±40)
ND
3.9 (±1.6)
10.0 (±0.68)
ND
ND
ND
ND
167.5 (±43.6) 362.1 (±33.3)
5.7 (±3.0)
29.0 (±2.7)
26.0 (±6.0) 158.9 (±31.7)

Substrate Turnover
Kcat pABA
Kcat SMX
(s-1)
(s-1)
4.5 (±0.4)
2.2 (±0.1)
1.7 (±0.3)
1.0 (±0.1)
3.4 (±0.2)
1.6 (±0.1)
1.9 (±0.2)
0.8 (±0.1)
3.1 (±0.0)
1.5 (±0.1)
1.8 (±0.0)
0.9 (±0.2)
0.5 (±0.0)
0.3 (±0.1)
0.5 (±0.1)
0.3 (±0.0)
3.6 (±0.3)
2.1 (±0.2)

measured, and it was found that the mutations generally decrease turnover two-fold with
an even further decrease in turnover with the E208K combinations (Table 2-4).
Resistance profile of an S. aureus isogenic DHPS mutant panel against sulfonamide
drugs
To study the five DHPS mutations directly associated with sulfonamide resistance
from a whole cell standpoint, a set of eight isogenic S. aureus DHPS mutants were
generated in the USA300 AH1263 strain background. These isogenic strains harbored
both the primary and secondary mutations either as single mutations or in their clinical
combination (Tables 2-1 and 2-2). All mutants were successfully cloned with the
exception of the T51M E208K combination. The S. aureus COL strain, which naturally
harbors the T51M E208K set, was included for select experiments. The susceptibility of
this panel of isogenic strains was tested against a variety of sulfonamide drugs (Table 25). Chloramphenicol (CAM) was included as a control since its MOA is distinct from the
antifolates. To avoid interference of metabolites common in rich testing medias with
minimal inhibitory concentration (MIC) determination, MICs were performed in the
SSM9PR minimal media which lacks pABA and various folate derivatives (Reed 2015).
All strains tested had very similar CAM MICs (Table 2-5). Among the primary
mutants, F17L generally showed the most marked increases in sulfonamide MICs
compared to the WT strain, with at least a two-fold MIC shift for seven of the ten
sulfonamides tested. S18L and T51M showed less dramatic increases in susceptibility.
Among all of the sulfonamides tested, the T51M single mutant only showed an MIC shift
greater than two-fold for dapsone. In the case of T51M, this is notable due to the
corresponding mutation being observed in M. leprae, Pneumocystis spp., and
Plasmodium spp. In patients with sulfa allergies, dapsone is a common prophylactic
treatment option in combination with TMP for Pneumocystis pneumonia in
immunocompromised patients (Hughes 1998). Dapsone is also used in the treatment of
both leprosy and malaria (Saha 2003). The use of dapsone to treat infections in these
species likely encouraged this loop 2 mutation, which appears to have specific effects
towards dapsone.
The two secondary mutations, E208K and KE257_dup, are located in less
conserved regions of the enzyme that are more disparate from the active site locale.
Therefore, their roles in resistance are unclear. Secondary mutations do not always show
resistance on their own but may compensate for a fitness cost associated with primary
mutations (Sander 2002). However, both DHPS secondary mutations alone showed
moderate increases in MIC for many of the sulfonamides tested, indicating they have
direct contributions to resistance as opposed to strictly serving as compensatory
mutations (Table 2-5).
The susceptibility profile of strains with mutations in combination showed the
strongest increases in resistance among the entire mutant panel. In the case of the
combination mutations in the isogenic set (F17L E208K and F17L KE257_dup), the
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Table 2-5.

MIC80 Values for S. aureus Isogenic DHPS Mutant Panel (μg/mL).
No
Mutation

Compound
Sulfacetamide
Sulfathiazole
Sulfamethoxazole
Sulfisoxazole
Sulfapyridine
Sulfadiazine
Dapsone
Sulfamethoxypyridazine
Sulfadimethoxine
Sulfadoxine
Chloramphenicol
Trimethoprim
SMX/TMPb

WT
25.0
2.6
4.2
2.1
33.3
10.4
16.7
7.3
2.6
25.0
4.2
1.6
0.39/
0.021

Primary Mutation
F17L
41.7
12.5
16.7
6.3
100.0
25.0
20.8
25.0
12.5
33.3
4.2
0.065
0.78/
0.041

S18L
20.8
4.2
10.4
5.2
50.0
25.0
6.3
25.0
4.2
41.7
3.1
0.024
0.33/
0.017

Secondary Mutation

T51M
12.5
3.1
6.3
2.1
66.7
8.3
50.0
7.3
3.6
12.5
3.1
0.16
0.39/
0.021

a

E208K
50.0
8.3
8.3
6.3
50.0
20.8
33.3
12.5
8.3
50.0
3.1
1.6
0.52/
0.027

Combination

F17L
F17L
KE257_dup E208K KE257_dup
41.7
200.0
133.3
8.3
41.7
41.7
8.3
50.0
41.7
6.3
25.0
25.0
50.0
200.0
200 - >200
20.8
83.3
83.3
29.2
50.0
66.7
16.7
83.3
83.3
8.3
33.3
25.0
41.7
200.0
83.3
3.1
3.1
3.1
1.0
0.16
0.20
0.65/
1.6/
1.6/
0.034
0.082
0.082

T51M
E208Ka
200 - >200
83.3
66.7
58.0
>200.0
200.0
200 - >200
133.3
66.7
200 - >200
3.1
2.1
3.1/
0.16

The S. aureus COL strain was used to represent the T51M E208K combination since the isogenic mutant harboring this mutation set
could not be generated.
b
SMX/TMP combination was prepared at a 19:1 combination.

25

combination MIC exceeded the combined MICs of the primary and secondary mutations
alone for nearly all sulfonamides. The COL strain representing the T51M E208K set had
the highest MIC values overall, but genetic variations in this strain could have additional
effects on susceptibility (Table 2-5).
Altered susceptibility of isogenic mutants to TMP and co-trimoxazole
To explore the potential for effects of DHPS mutation-induced collateral
sensitivity against DHFR-targeted agents, the TMP susceptibility among the isogenic
mutants was determined both alone and in combination with the common partner drug
SMX. DHFR is two steps downstream of DHPS in the FBP and targeting both enzymes
with the co-trimoxazole combination results in synergy (Figure 1-2).
Interestingly, the primary mutations imparted a remarkable decrease in the MIC
for TMP. Secondary mutations alone had negligible changes to the TMP MIC, but the
MICs among the double mutants showed a partial restoration of TMP susceptibility
closer to WT levels of 1.6 μg/mL (Table 2-5 and Figure 2-3). The addition of pABA to
the testing media universally restored the MIC for all affected strains (Figure 2-3). This
provides interesting implications as to how closely the enzymes of the FBP are
interconnected, which could explain the synergy observed within the co-trimoxazole
combination. Primary DHPS mutations were shown to impart a fitness cost in terms of
biochemical function (Table 2-4), which likely renders the downstream enzyme DHFR
more crucial to overall cell viability, resulting in a collateral sensitivity effect towards
TMP. Secondary mutations appear to not only increase sulfonamide resistance, but also
rescue defects in both biochemical fitness (Table 2-4) as well as restore the TMP and cotrimoxazole MIC (Table 2-5). Addition of pABA may boost the catalytic output of
DHPS and outcompete sulfonamides, reducing the downstream consequences of primary
mutation on DHFR. These effects highlight the interplay between the two enzymes and
suggests the synergy and efficacy of the co-trimoxazole combination can be attributed to
collateral sensitivity effects occurring within antifolate combination therapy.
Although co-trimoxazole is formulated at a SMX/TMP ratio of 5:1, in vitro
testing typically occurs at a ratio of 19:1 to mimic the ratio of both drugs achieved in the
serum after oral administration (Rein 1980). The mutant strains were tested against this
combination and MICs were determined (Table 2-5). The single mutations did not show
notable increases in resistance to the combination, but the increase in resistance among
double mutants was at least three-fold. Although the primary mutations were more
sulfonamide resistant than secondary mutations alone, the increased TMP susceptibility
maintained the co-trimoxazole MIC closer to WT levels, with only a two-fold increase
seen for F17L which showed the strongest overall resistance to the sulfonamide panel as
a single mutant. When a primary mutation is present, a secondary mutation may be
necessary to compensate for the heightened TMP susceptibility and impart high-level
resistance to the SMX/TMP combination. Therefore, in addition to restoring biochemical
fitness (Table 2-4), secondary mutations rescue the collateral sensitivity imparted by
DHPS primary mutations towards TMP (Figure 2-3).
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Figure 2-3. Trimethoprim susceptibility profile of isogenic DHPS mutant panel.
This data represents the TMP MIC data in Table 2-5 and includes additional MIC values
determined in the presence of pABA supplementation. The presence or absence of 5
µg/mL pABA is represented by a + or – sign, respectively.
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Growth curve studies
To determine whether the DHPS mutations directly associated with resistance
resulted in reduced fitness, growth rates were determined for each mutant either as single
mutations or in their observed clinical combination. It was found that only the S18L and
T51M primary mutations had a significant impact on doubling time (Figure 2-4). This
indicates that mutations in the flexible loop region where both native substrate pABA and
sulfonamides bind results in the highest fitness cost. However, F17L, which resides in
the flexible loop region, did not show a fitness cost in this model. The higher-level
resistance of F17L in comparison to the other primary mutations and the lack of an
associated fitness cost may explain its frequency in S. aureus and other organisms in
comparison to the other two primary mutations (Tables 2-2 and 2-3).
Galleria mellonella infection model
The larvae of the greater wax moth, Galleria mellonella, can serve as cheap and
effective host organisms for in vivo rescue experiments (Ramarao 2012, Tsai 2016). This
model was used to study both the virulence and resistance of the isogenic mutants from
an in vivo standpoint. The wax moth larvae infection model was first optimized to
determine the inoculum density necessary to achieve a median lethal dose (LD50) with
the WT strain at 72 hours post-infection. This three-day time span allows the opportunity
for several live/dead counts before the larvae begin the pupation stage (Tsai 2016).
Using the USA300 AH1263 WT strain to optimize this model, it was found that
approximately 105 colony-forming units (CFU) of bacteria per injection could achieve
approximately 50% mortality at 72 hours (Figure 2-5A).
To test for resistance in this model, it is necessary to be able to rescue the larvae
hosts from WT infection using a sulfonamide. It was found that SMX is soluble in a
carrier solvent of PBS and 5% DMSO up to 100 mg/mL. Daily administration of 100
mg/kg SMX resulted in a significant rescue of the larvae from WT infection (Figure 25B). A control group receiving an equivalent number of injections per day with the
PBS/DMSO carrier showed minimal death over the 72-hour span.
The entire isogenic mutant panel was subjected to this infection model to monitor
for any significant reduction in virulence. No significant difference was observed
according to the Mantel-Cox (Log-Rank) analysis of mortality-based virulence among all
of the mutants relative to the WT strain (Figure 2-6). However, overall mortality rates at
the end of the study were lowest for S18L and T51M, which agrees with the reduced
fitness represented by increased doubling times observed in the growth rate study (Figure
2-4). Interestingly, none of the mutants could be rescued by SMX treatment, indicating
the resistance observed during MIC testing translates to in vivo resistance. This also
confirms that the secondary mutations are not simply abrogating a fitness cost, but that
they have direct roles in sulfonamide resistance.
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Figure 2-4. Doubling times of the isogenic DHPS mutant panel in S. aureus.
Doubling times were determined during the exponential growth phase of each strain.
Significant differences in doubling times were determined by Dunnett’s multiple
comparisons. **indicates p < 0.05, ***indicates p < 0.001.

Figure 2-5. Optimization of wax moth larvae infection model.
A. Determination of USA300 inoculum density required to reach an LD50 at
approximately 72 hours. B. SMX rescue of USA300 infection in G. mellonella infection
model. *** indicates P < 0.001 using Mantel-Cox (Log-Rank) survival analysis.
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Figure 2-6. Galleria mellonella virulence and rescue study.
Mortality data are represented as a dot plot, with each dot representing an observed death.
Closed dots are untreated larvae and open dots are SMX-treated larvae. ***indicates P <
0.001 via Mantel Cox (Log-Rank) survival analysis.
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Structural characterization of the DHPS resistance mutations
In order to study the DHPS resistance mutations from a structural standpoint, an
X-ray crystallography study was initiated on all recombinant mutant proteins. The DHPS
structure has a notable degree of disorder within the flexible loop system where both
pABA and sulfonamides bind. This has caused the structural study of the active site
region of DHPS from S. aureus and other species to be especially difficult (Hampele
1997). Crystallization and data collection were attempted on all variant enzymes, but
only the F17L E208K structure was successfully obtained. This mutant structure was
solved both in the apo state and in complex with 1530, which is a pterin-sulfisoxazole
conjugate (Zhao 2016, Compound 16).
Although only the F17L E208K protein could be characterized through X-ray
crystallography, the resulting structures provided valuable information on resistance
mechanisms imposed by both mutations. Previously reported structures of Y. pestis
DHPS in the transition state were valuable in the study and modeling of the active site
locale and adjacent salt bridge array affected by secondary mutation (Yun 2012).
Fortunately, several of the active site residues are well conserved between the two
species. Modeling of the SaDHPS transition state using YpDHPS 3TYZ predicted
several of the loop 1-2 residues known to coordinate binding of pABA and SMX likely
maintained the same roles in S. aureus. S18 does not appear to have direct interactions
with pABA but may have stabilizing effects on loop 1. T51 interacts with the pABA
amino group through hydrogen bond formation and stabilizes the amino group of the C11
carbon of DHP to assist in bond formation with pABA (Figure 2-7A).
The crystal structures of both apo- and 1530-bound SaDHPS with the F17L
E208K double mutation were compared with the modeled SaDHPS transition state
structure. The L17 residue in loop 1 of both structures assumes a similar position in the
unbound structure to that of F17 in the modeled transition state, suggesting L17 may
sterically interfere with the sulfonamide portion of 1530 (Figure 2-7A, B). The direct
steric impact of the F17L mutation on sulfonamide binding was an expected effect given
that it is located directly in the active site binding region of sulfonamides.
Compared to the primary mutations, the mechanisms of resistance imposed by the
E208K secondary mutation are less immediately obvious. Structural studies, however,
revealed an E208K-mediated mechanism of disfavoring inhibitor binding. E208 is part
of a salt bridge array wherein E208 forms a salt bridge with R176, E179 forms a salt
bridge with R204, and the two arginines at positions 176 and 204 interact by π-stacking.
This array in the WT SaDHPS structure from 1AD1 is represented in Figure 2-7D. In
the mutated structure, however, R204 is displaced and positioned so that it seems to
sterically disfavor the position of the oxazole ring of 1530 which extends beyond the
molecular space occupied by pABA. R176 forms a salt bridge with E179 instead of
E208, suggesting disruption of the WT salt bridge array is an indirect mechanism of
sterically disfavoring sulfonamide binding through mutation of E208.
These findings on the perturbation of the sulfonamide binding site induced by
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Figure 2-7. Structural characterization of the WT and F17L E208K salt bridge
array.
A. SaDHPS transition state modeling based on the Y. pestis (PDB 3TYZ) structure. The
DHPS protein is represented in green cartoon, highlighted residues are green carbon with
stick representation, the ligands DHP and pABA are both in stick representation with
magenta and salmon carbons, respectively, while PPi is orange. The magnesium cofactor
is represented as a green ball. B. Crystal structure of the S. aureus F17L E208K salt
bridge array. The protein in cartoon representation is shown in purple, and the residues
are in stick representation with purple carbons. C. Crystal structure of F17L E208K salt
bridge array in complex with 1530. The DHPS protein is in yellow cartoon, the residues
are represented by yellow sticks, and 1530 is represented by orange sticks. D. WT
SaDHPS salt bridge array proximal to the active site from the SaDHPS crystal structure
1AD1. The coloring and representation are the same as panel A. Salt-bridges and
hydrogen bonds are represented by dashed gray lines for all panels.
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E208K emphasize the unexpected roles that secondary mutations can have on resistance.
Pathogens can clearly develop sophisticated mechanisms through target alteration in
regions distal from the site of drug binding. Before this work, sulfonamide resistance
mutations were generally understood to exist directly in the active site loops 1 and 2,
which directly interact with both sulfonamides and pABA, but resistance in S. aureus can
apparently occur through additional secondary mutations that have indirect effects on
sulfonamide binding site structure and additive effects on resistance (Table 2-5). Since
the secondary mutation E208K occurs in a region of DHPS that is not well conserved in
other species (Figure 2-2), this appears to be a resistance mechanism unique to S. aureus.
These findings on the impact of mutations on regions extending beyond the binding sites
of native substrates emphasize that next-generation inhibitors must remain within the
substrate envelope to avoid impaction by mutations that readily arise against
sulfonamides in clinical isolates. Studies on resistance mutations in hepatitis C virus also
revealed that the highest level of resistance was also acquired by mutation against
inhibitors extending beyond the molecular space within the substrate envelope (Romano
2010).
Conclusions and Future Perspectives
The basis for resistance caused by primary mutations within the loop 1-2
substructure are well characterized in this study and others, and the structural basis for
resistance imparted by the E208K secondary mutation was explained for the first time in
this body of work. Unfortunately, attempts to study the KE257_dup secondary mutation
through X-ray crystallography were unsuccessful. An intriguing study characterizing the
DHPS dimer interface for allosteric inhibitor development suggested interactions at this
site influence breathing motions within the dimer that facilitate substrate release
(Hammoudeh 2014). The dimer interface clearly imparts allosteric effects on the active
site, but the exact basis for sulfonamide resistance achieved through alteration of this site
has yet to be revealed.
The FBP remains promising for further drug discovery efforts due to the role of
folates in numerous fundamental cell processes as well as the absence of many enzymes
including DHPS from mammals (Bermingham 2000). As with all other major classes of
antibiotics, the efficacy of our current arsenal of sulfonamides is threatened by continued
observation of sulfonamide resistance globally. Effective next-generation DHPS
inhibitors must be refractory to circulating mechanisms against established sulfonamides.
In order to improve the current understanding of sulfonamide resistance mechanisms, a
comprehensive characterization of DHPS mutations directly attributed to sulfonamide
resistance was carried out using biological, structural, and biochemical approaches. The
results presented within this chapter present important implications for future drug
development towards DHPS. It was found that mutations in both the flexible loop region
as well as in disparate regions of the enzyme influence the portion of sulfonamides that
extends out of the substrate envelope (Figure 2-7). Therefore, next-generation DHPS
inhibitors must avoid this molecular space that is most susceptible to circulating
sulfonamide resistance mutations.
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Ongoing DHPS inhibitor development within our laboratory currently avoids
probing the space beyond the DHPP/pABA substrate envelope. These inhibitors are
expanding upon the pyridazine inhibitor series and are designed to remain within the
conserved pterin binding site, wherein no resistance mutations are known to occur (Lever
1985, Zhao 2012). Beyond DHPS, there are also several enzymes of interest for inhibitor
development within the FBP and related branches of bacterial metabolism. In the next
chapter, further drug discovery efforts towards bacterial metabolism are pursued by
employing a high throughput metabolic screen for new small molecule inhibitors
disrupting metabolic processes related to folate biosynthesis.
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CHAPTER 3. METABOLIC PROFILING OF ANTIFOLATES LEADS TO A
SCREEN FOR NEW INHIBITORS OF BACTERIAL METABOLISM
Introduction
Metabolic networks associated with tetrahydrofolate are promising avenues for
drug discovery
The current antibiotic arsenal generally only targets a limited number of cell
processes, including DNA synthesis, protein synthesis, and the cell wall (Haselbeck
2002, Brown 2013). New antimicrobials with unique MOAs would provide crucially
needed treatment options when target-mediated resistance is presented against traditional
antibiotic classes. A rich source of potential new antibiotic targets lies within bacterial
metabolism, which is evolutionarily distinct from higher eukaryotes.
There is promising potential for antibiotic discovery towards both existing and
new targets within the FBP (Sköld 2000, Zlitni 2013). Additionally, several allied
pathways responsible for crucial metabolic processes are yet to be fully exploited for
antibiotic discovery. Drug discovery campaigns towards bacterial metabolism have
gained stamina in recent years using both structure-based and in vitro screening
methodologies. Structure-based studies have allowed for the generation of improved
inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase, which is
immediately upstream of DHPS within the FBP (Dennis 2016). Propargyl-linked
antifolates (PLAs) are showing the potential to successfully inhibit drug-resistant forms
of DHFR, the final enzyme in the FBP, in MRSA strains (Reeve 2016). Recently, an
inhibitor of pABA biosynthesis was discovered in a differential metabolic screen in E.
coli (Zlitni 2013). Beyond folate biosynthesis, the same screen identifying the pABA
biosynthesis inhibitor also characterized inhibitors of biotin biosynthesis and glycine
metabolism. Furthermore, an allosteric inhibitor of tryptophan synthase has recently
been identified from a whole cell M. tuberculosis screen against a diversity-oriented
synthetic library (Wellington 2017).
Obstacles of antimetabolite drug discovery
A common issue with early stage development of antimetabolites is the fact that
nutrients within common testing media can interfere with the ability of certain
antimicrobials to inhibit bacterial growth. The MICs of antimetabolites representing both
experimental and existing antibiotic compounds are known to be masked by nutrient-rich
testing medias (Zlitni 2013). When the product of a target enzyme is available to the cell
in sufficient quantities, i.e. nutrients within the media, inhibiting the function of the
enzyme may not result in growth inhibition as there is no starvation effect. Furthermore,
bacterial metabolism is extensively regulated, and the transcription of the biosynthetic
machinery is often dependent on closely associated metabolites (Baba 2006). In a
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nutrient-rich environment, the intended antimicrobial target may not be expressed in
sufficient quantities for the intended growth inhibitory effect. Conversely, in the absence
of specific metabolites, the transcription of de novo biosynthetic machinery is often
greatly upregulated and necessary for survival. This drastic change in gene transcription
has been observed in E. coli, wherein 119 genes are known to be essential in a minimal
nutrient environment, but dispensable in rich growth media (Baba 2006).
Mueller Hinton (MH) and lysogeny broths (LB) are very common bacterial
testing media, but they are rich in peptides and vitamins that represent both intermediates
and downstream products of folate biosynthesis. Isosensitest broth (ISB) is often used for
antifolate susceptibility testing due to significantly reduced concentrations of thymidine
and pABA, but this media is still rich in peptides. Various amino acids are downstream
products of folate biosynthesis and methionine is known to mask antifolate MICs (Zlitni
2013). Molecules in early-stage development often have MICs that are close to the upper
limit of detection, and even a subtle decrease in potency can cause the MIC to be
undetectable. This inability to detect a MIC dramatically hinders the ability to improve
biological activity through a structure-activity relationship (SAR) approach.
A preferred testing media for early-stage development of antifolates and other
antimetabolites would completely lack all amino acids and as many vitamins as possible.
The high-throughput screen (HTS) carried out by Zlitni and colleagues, which identified
the inhibitors of pABA biosynthesis, biotin biosynthesis, and glycine metabolism in E.
coli, was carried out against whole cell E. coli in the M9-based minimal media ATCC
2511 (Zlitni 2013). Initial indications of the MOA of the primary hits was evaluated with
“rescue studies” carried out by adding individual metabolites to the M9 media to test for
antagonism of the growth inhibitory action of these molecules. This screen yielded
several interesting new antimetabolite compounds, including MAC173979, which is an
inhibitor of pABA biosynthesis and is very closely linked to folate biosynthesis (Zlitni
2013). The potency of this hit compound could be antagonized by supplementation with
both pABA and L-methionine, which is a similar metabolic profile to that of conventional
sulfonamide drugs.
Within this chapter, whole cell testing conditions are optimized to detect the
growth inhibition of next-generation antifolates against the GN pathogen E. coli without
the interference of metabolites related to folate biosynthesis. The inclusion of two
additional testing conditions in the presence of the DHPS substrate pABA and the folate
derivative methionine result in detectable MIC shifts indicating an interaction with the
target pathway. This approach augmented an SAR study of a novel series of pterinsulfonamide conjugates designed to simultaneously engage two distinct binding sites on
the DHPS enzyme.
These conditional antimetabolite testing methods were adapted to a HTS for small
molecule inhibitors of E. coli. A Bioactives collection of known therapeutics including
antibiotic antifolates confirmed this screening approach, after which approximately
13,000 compounds were screened. After excluding known antibiotics, a collection of
validated hits with varying sensitivity to the amino acid methionine were obtained. These
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hits consisted of both existing therapies characterized for human targets as well as a
variety of small molecules yet to be characterized for biological activity. These efforts
have yielded tools for better detection and improvement of biological activity of novel
antifolates. Additionally, the HTS resulted in a collection of new GN-effective inhibitors
that could potentially have an exciting new antimetabolite MOA in a time when new
first-in-class inhibitors are desperately needed.
Materials and Methods
Differential susceptibility testing in M9 minimal media
MIC broth dilution testing was performed as previously described in Chapter 2.
E. coli K12 MG1655 was purchased directly from ATCC and only cultured in M9 for
initial and subsequent stock generations to avoid auxotrophy. MIC determination of
pterin-sulfa conjugates, primary screening, and secondary validation experiments were all
carried out in M9 using this strain. M9 media was prepared as described for ATCC
media 2511. For every liter of media, 200 mL of 5X M9 salt solution, 20 mL of 20% w/v
glucose, 2 mL of 1 M MgSO4, 0.1 mL CaCl2, and 0.1 mL of a 0.5% w/v solution of
thiamine were combined and brought to the final volume and filter-sterilized. When
needed, supplements were added at concentrations of 5 μg/mL for pABA or 20 μg/mL for
L-methionine.
High throughput screen in nutrient-restricted media
Thirteen microliters of M9 media was dispensed into each well of a Nunc 384well optical bottom plate using the Thermo Scientific Wellmate Matrix Dispenser. A
PerkinElmer BackSeal was applied to the bottom of the plate to accommodate
luminescence reads. Source plates containing approximately 10 mM compound were
used to stamp 121 nL into the assay plate using a Biomek FXP Automated Liquid
Handler. Columns 1, 2, 13, and 14 were reserved for controls, into which CAM or SMX
were added from a control plate. A mid-log culture of E. coli K12 MG1655 was diluted
to an OD600 of 0.001 in ATCC medium 2511 before dispensing 13 μL into each well of
the drugged assay plates using the Thermo Scientific Wellmate Matrix Dispenser,
resulting in 1.3 x 104 CFU per well. Concentrations varied slightly in the library source
plates, but the final assay concentration for each compound was approximately 50 µM.
After 16 hours of incubation at 37° C, 26 μL freshly prepared BacTiter-GloTM was
added to each well. The plates were allowed to shake for four minutes followed by a
luminescence read within thirty minutes of adding the reagent. Four columns total were
committed to controls, with two of these columns containing two-fold serial dilutions of
both CAM and SMX. Therefore, MICs of these standard drugs could be determined
within each plate, and the MIC of SMX was shifted by the addition of pABA and
methionine. The other two columns containing alternating wells with either 50 μM CAM
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or DMSO, representing full inhibition or full growth, and were used to calculate the Zfactor of each plate. The high-throughput data was analyzed using the Robust
Interpretation of Screening Experiments (RISE) application, which was written with
Pipeline Pilot (Accelrys, v. 8.5) using the R program (R Core Team 2015).
Secondary validation of primary hits and testing for rescue effect
Hits from the primary screen that showed ≥ 50% growth inhibition were validated
using a traditional MIC assay. Three replicates of the MIC were performed on three
separate days. The resulting MIC values were averaged, and hits that maintained an
MIC80 of 50 µM or less were considered validated hits.
Results and Discussion
Minimal media conditions enable SAR study of pterin-sulfa conjugates
Antifolate compounds developed in our laboratory have displayed high affinity
engagement of DHPS and structural studies have shown that they interact with the
enzyme in areas that are less prone to common sulfonamide resistance mechanisms (Zhao
2012, Hammoudeh 2014). Despite these advantages, the measurement of biological
activity under standard testing conditions is an obstacle towards the further development
of these compounds. Similar to conventional antifolates, it is likely that nutrients present
in standard testing media interfere with the detection of growth inhibition.
A new series of pterin-sulfa compounds were developed to simultaneously engage
the DHPS enzyme in the conserved DHPP binding site and the traditional sulfonamide
binding site (Zhao 2016). Eight molecules were synthesized with a fixed pterin moiety
conjugated to each of eight different sulfonamides (Table 3-1). Instead of the rich MIC
testing broths LB, MH, and ISB, a M9-based minimal media broth (ATCC 2511 or M9)
was used to test for MIC activity.
The pterin-sulfa compounds have no detectable MIC against E. coli in either MHII or ISB (data not shown). When these compounds were tested in the M9-based media
ATCC 2511 (M9), however, MICs against E. coli K12 were observed to be as low as
10.9 μM (Table 3-1). Similar to the antifolates tested in the Zlitni et al. study, the action
of these conjugates could be strongly antagonized by pABA and to a lesser extent Lmethionine (Zlitni 2013, Zhao 2016). The corresponding sulfonamides were also tested
and displayed a similar pattern of antagonism through supplementation (Table 3-1).
Furthermore, the potency of the pterin-sulfa conjugates had a high degree of correlation
with the potency of the associated sulfonamide.
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Table 3-1.

The MICs of pterin-sulfa conjugates can be rescued by metabolites related to folate biosynthesis.

Compound #

R

M9 media

Minimal inhibitory concentration E. coli K12, in µMa
M9 plus 5 µg/mL pABA
M9 plus 20 µg/mL methionine

15

10.9 (0.8)b

467 (263)

29.0 (1.5)

16

28.3 (1.5)

>412 (249)

47.0 (5.9)

17

17.1 (1.6)

>470 (666)

78.0 (6.2)

18

29.5 (2.7)

>471 (669)

98.0 (6.3)

19

17.2 (1.6)

>412 (537)

86.0 (3.4)

20

34.3 (3.8)

>412 (>644)

172 (10.1)

21

197 (25)

236 (>934)

236 (50)

22

136 (22)

>514 (>934)

>200 (58)

Ampicillin

1.6

2.0

2.1

Chloramphenicol

8.5

9.7

9.7

Trimethoprim

1.7

1.4

0.7
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Table 3-1.

Continued.

Modified with permission from Zhao Y, Shadrick WR, Wallace MJ, Wu Y, Griffith EC, Qi J, Yun MK, White SW, Lee RE. Pterinsulfa conjugates as dihydropteroate synthase inhibitors and antibacterial agents. Bioorg Med Chem Lett. 2016 Aug 15;26(16):3950-4.
a
Average of 3 experiments.
b
Corresponding values for parent sulfonamides shown in parentheses.
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Assay validation for the conditional metabolic screen through a preliminary screen
of known Bioactive compounds
The revealed activity of the pterin-sulfa series against the GN pathogen E. coli
K12 enabled the potential for pursuing a HTS for new antimetabolites that could inhibit
the growth of this clinically significant pathogen. The primary screen would be
conducted in the minimal media environment to avoid interference of MIC activity by
metabolites present in the testing media. Two additional conditions, the presence of
pABA or L-methionine, could be included as an indication of interaction with the
biosynthesis of folate and closely related pathways (Zlitni 2013).
To investigate the feasibility of this screening approach, a library of Bioactive
molecules was initially tested. This library consists of 1,831 molecules with known
biological activity and therapeutic utility against a wide range of maladies such as cancer,
cardiomyopathies, and infections. A range of antibiotic classes including sulfonamide
drugs and other antifolates are also present in this library, allowing for several internal
controls for both E. coli growth inhibition and the conditional metabolic screen. The
initial screen was set up in 384 well plates with designated wells for the positive control,
CAM, and the negative control, DMSO, representing 100% growth inhibition and no
growth inhibition, respectively. An internal assay control represented by a SMX doseresponse was also included to show that antagonism by pABA and L-methionine could
be achieved. Each drug from the Bioactives collection was added to the assay plates at a
final concentration of approximately 50 µM in M9, and the plates were inoculated and
incubated similar to a standard MIC (see methods). Growth inhibition was determined
based on a luciferase-based readout that is sensitive to the amount of ATP in each well,
corresponding to the number of viable cells.
The Robust Interpretation of Screening Experiments (RISE) application was
utilized for analysis of the screening data (R Core Team, 2015). Z-factors ranging
between 0.43 and 0.69 were achieved within the Bioactives screen, with an average Zfactor of 0.59 (Figure 3-1), indicative of an excellent assay (Zhang 1999). Only four
plates were slightly below this threshold.
In addition to the Z-factor calculations for the control compounds, the data for all
molecules within the Bioactives screen were again analyzed using RISE. Out of the
1,831 compounds, 78 exhibited at least 50% growth inhibition relative to the internal
controls, resulting in a hit rate of 4.3%. Most of these hits were known antimicrobial
compounds. When these antimicrobial compounds were categorized by MOA, it was
apparent that antifolates indeed showed a unique metabolic profile, with the action of
nearly all antifolates, with the exception of TMP, being completely antagonized by
pABA. Methionine rescued the growth inhibition of antifolates to a lesser extent, and
also exhibited an effect on some inhibitors of DNA and protein synthesis (Figure 3-2).
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Figure 3-1. Z factors observed for the preliminary Bioactives screen.
Z-factors are determined based on internal positive and negative controls in each assay
plate. Blue dashed line at 0.5 represents the threshold for an excellent assay. Red dashed
line at 0.59 represents the average Z-factor of the Bioactives screen.

Figure 3-2. Growth inhibition and antagonism by key metabolites observed by
known antimicrobials in the Bioactives collection.
Blue dots represent percentage growth inhibition in M9 media. Red and green dots
represent percentage growth inhibition in the presence of either 20 µg/mL methionine or
5 µg/mL pABA, respectively.
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High-throughput screen of nearly 13,000 compounds
Since the quality of the HTS methods and antimetabolite detection strategy was
successfully validated using the Bioactives collection, the HTS was further expanded to
three additional libraries including a set of “Lead-Like” molecules, a Small Fragment
library, and an in-house library of antifolates. This led to a total of 12,597 molecules that
underwent the HTS. The Lead Like set consists of 10,041 molecules with diverse
chemical scaffolds that are suitable for lead optimization with a molecular weight at or
below 400. The small fragment library is comprised of 750 compounds, wherein 98% of
the molecules in this set have a molecular weight below 200. Finally, a collection of
antifolate compounds generated in-house was assembled. This consisted of 335
compounds in total, with ten of them being established sulfonamides.
Due to the large number of compounds included in the screen, these three
additional libraries were first screened only in M9. The growth inhibition threshold for
hit determination was again set at 50%, and 136 primary hits were obtained, resulting in a
primary hit rate of 1.1% for the entire screen in M9 (Figure 3-3A). When the percentage
growth inhibition of all experimental compounds and controls were plotted on a scatter
plot, it was found that there was an adequate degree of separation between positive and
negative controls (Figure 3-3B). To further assess the quality of the primary screen, Zfactors were calculated for all M9 screening plates for all compounds tested. The average
Z-factor was 0.62, and all but one of the assay plates had a Z-factor above 0.5 (Zhang
1999) (Figure 3-4).
Secondary validation of primary hits
Among the primary hits showing ≥50% growth inhibition against E. coli, 54
molecules had no previously characterized antimicrobial activity and were selected for
secondary analysis. These molecules underwent traditional MIC testing in
unsupplemented M9, M9 with 20 µg/mL methionine, and M9 with 5 µg/mL pABA.
Nineteen compounds had an MIC80 of ≤50 μM and were considered validated hits (Table
3-2).
Most of the validated hits originated from the Bioactives or Lead-Like libraries,
and one compound originated from the Small Fragment Library. From the Bioactives
collection, the validated hits were mostly oncological agents disrupting metabolic
processes related to DNA. Notably, five inhibitors of thymidylate synthase (TS) were
confirmed secondary hits (Table 3-2). These drugs are all analogs of fluorouracil.
Although not situated directly in the classic FBP, TS is only two enzymatic steps
downstream of THF (Figure 3-5). TS converts deoxyuridine monophosphate (dUMP) to
deoxythymidine (dTMP), which is one of the four nucleotide bases in DNA. N5,N10methylenetetrahydrofolate acts as a methylene and hydride donor during this reductive
methylation reaction. Along with dTMP, 7,8-dihydrofolate is also produced during this
reaction and recycled back to DHFR at the last step of the FBP.
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Figure 3-3. HTS of nearly 13,000 compounds in nutrient-restricted broth.
A. Schematic of the overall screen. B. Scatter plot of percentage E. coli growth
inhibition in M9 for all compounds tested. Dashed line at 50% growth inhibition
indicates the minimum percentage of growth inhibition required for hit determination.
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Figure 3-4. Z factors of the entire screen, M9 only.
Blue dashed line at 0.5 represents the threshold for an excellent assay. Red dashed line at
0.62 represents the average Z-factor for the complete primary screen in M9.
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Table 3-2.

Validated hits from the conditional metabolic screen.

Common
Name/SJ#

µM
MIC80a

Fold Shift MICb
Methioninec
pABAd

Screening
Library

5-fluorouracil

0.16

-

-

Bioactives

Carmofur

0.20

-

0.75

Bioactives

Floxuridine

0.21

1.3

-

Bioactives

Decitabine

0.32

1.6

0.83

Bioactives

Azacytidine

1.5

0.71

0.71

Lead-Like

Zebularine

1.8

-

0.75

Bioactives

Bleomycin

3.1

-

0.67

Bioactives

STATTIC
Pifithrin

4.5
6.5

2.0
2.0

-

Bioactives
Bioactives

Cladribine

8.9

1.7

-

Bioactives

SJ000208968

12.6

4.0

-

Lead-Like

Doxifluridine

14.3

-

0.88

Bioactives

18.1

1.3

-

Bioactives

20.9
25

4.8
5.3

-

Lead-Like
Lead-Like

Cisplatin
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2.4

-

Bioactives

SJ000866485

44

-

-

SJ000208489
SJ000129420
Chloramphenicol
Sulfamethoxazole
Trimethoprim

50
50
5.0
0.39
0.69

5-fluoro-1(tetrahydro-2furfuryl)uracil
SJ000461885
SJ000209472

5.3
3.3
1.3
2.0
-

1.0
849
-

a

Small
Fragment
Lead-Like
Lead-Like
NA
NA
NA

Mechanism of Action
Thymidylate synthase
inhibitor
Thymidylate synthase and
acid ceramidase inhibitor
Thymidylate synthase
inhibitor
DNA methyltransferase
inhibitor
Cytidine analog, treats
myelodysplastic syndrome
Cytidine analog, epigenetic
therapy
Induces DNA strand
breaks
STAT3 inhibitor
HSP70 inhibitor
Purine analog, inhibits
adenosine deaminase
Unknown
Thymidylate synthase
inhibitor
Thymidylate synthase
inhibitor
Unknown
Unknown
Inhibits DNA replication,
crosslinks purine bases
Unknown
Unknown
Unknown
Control antibiotic
Control antibiotic
Control antibiotic

MIC values and MIC shifts are an average of three replicate experiments.
Fold shift MIC is the ratio of supplemented MIC over unsupplemented MIC. If ratio is
equal to one, a dashed line is put in place of that data to represent an absence of an
observable MIC shift.
c
L-methionine was supplemented at a final concentration of 20 µg/mL.
d
pABA was supplemented at a final concentration of 5 µg/mL.
b
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Figure 3-5. Thymidylate synthase is closely linked to the FBP.
TS = Thymidylate synthase.
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Six other chemotherapeutic agents among the secondary confirmed hits also
disrupt nucleic acid metabolism as part of their MOA. These secondary hits were
decitabine, azacytidine, zebularine, bleomycin, cladribine, and cisplatin (Table 3-2). The
folate cycle is closely networked with several metabolic reactions related to DNA
metabolism and could potentially be engaged by these chemotherapies. The remaining
validated hits from the Bioactives library include STATTIC, BAY 11-7082, and pifithrin.
The targets of these chemotherapies are better studied and understood in mammalian
systems, and the potential targets in bacteria are unclear. Although these established
therapies have a confirmed effect on human targets, selectivity towards the target
enzymes in pathogenic species can be achieved through SAR.
Five compounds were validated hits from the Lead-Like library and one
compound was a validated hit from the Small Fragment library. The chemical scaffolds
of these six hits had no previously reported characterization as anti-infective agents
(Table 3-2). The MICs of these hits were not substantially altered by pABA
supplementation, but methionine shifted the MIC of nearly all of these compounds more
than two-fold. These compounds represent potential new antimetabolites that may have
exciting new MOAs against E. coli.
Conclusions and Future Perspectives
The rise of multi-drug resistant infections has led to a critical need for new and
druggable antibiotic targets. There are several unique candidate enzymes both within the
FBP and in closely related pathways in bacteria. The screening campaign carried out in
this study was intended to detect new small molecule scaffolds with an antimetabolite
MOA against E. coli. Growth inhibition in minimal media was measured within the
primary HTS, and then antimetabolite effects closely related to folate biosynthesis by
testing for MIC “rescue” with either pABA or methionine were identified during
secondary validation. Although the hit rate for GN whole cell screening is often very low
and the MOAs of lead compounds are not immediately apparent, the resulting hits from
whole cell screens have already met crucial checkpoints in that the molecules are GN
permeable and achieve adequate residence time to exert a growth inhibitory effect. For
these reasons, a general shift towards phenotype-based screening has been observed
among other drug discovery campaigns (Payne 2007, Zlitni 2013). The HTS presented in
this chapter initiated the approach of screening whole cell GN bacteria in a nutrientrestricted environment in the Lee laboratory. Similar screening approaches are ongoing
against recently developed compound libraries and other GN species with the hopes of
continually acquiring GN-effective antimetabolites
A total of nineteen validated hits were obtained from the nutrient-restricted HTS
presented in this study. Most of these hits originated from either the Bioactives library of
known biologically active molecules with diverse MOAs as well as the Lead-Like
library, which was the most extensive library tested consisting of over 10,000
compounds. The Bioactives library served as an ideal molecule set to pilot the primary
HTS. The diverse collection of antibiotics from several classes including the antifolates
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allowed for validation of the HTS methods and the metabolic rescue approach (Figure 32). Interestingly, various non-antibiotic hits passed secondary validation including
inhibitors of thymidylate synthase and other inhibitors of DNA synthesis as well as
STATTIC and pifithrin (Table 3-2). These therapies serve as candidates for drug
repurposing as antibiotics, which is a drug discovery method accruing interest in recent
years (Farha 2019). A significant advantage of drug repurposing is the fact that the drugs
of interest are already extensively characterized for the efficacy, safety, and metabolic
profile in humans. This can greatly expedite the clinical approval process.
In addition to the secondary hits originating from the Bioactives collection, five
validated hits originated from the Lead-Like library, which was the largest library
screened, and one validated hit originated from the Small Fragment collection. None of
these molecules have previously reported biological activity and their MOA against E.
coli is unknown. The fact that pABA does not shift the MIC of any of these compounds
suggests DHPS and pABA metabolism are likely not targeted directly by these
molecules. Methionine supplementation, however, imparted a significant shift in the
MIC for all five Lead-Like compounds (Table 3-2). This suggests these compounds may
have an antimetabolite MOA related to the biosynthesis of methionine. Investigation of
these compounds is continued in the next chapter.
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CHAPTER 4. DISCOVERY AND DEVELOPMENT OF THIOACETAMIDELINKED 1,2,3-TRIAZOLES TARGETING CYSTEINE SYNTHASE A
Introduction
Cysteine metabolism in microorganisms
Similar to folate biosynthesis, the cysteine biosynthetic pathway in bacteria is
unique from humans yet necessary for essential cell metabolites. Cysteine is an essential
metabolite with important cellular roles common to all domains of life. Cysteine is one
of the twenty standard amino acids found in proteins and aids in secondary structure and
stability through the formation of disulfide bonds. Additionally, cysteine can be found in
the active site of several enzymes as it is a strong nucleophile when oxidized. This amino
acid and various sulfur-containing derivatives, such as glutathione and taurine, can act as
an antioxidant using the thiol group to participate in redox reactions. Cysteine is also a
precursor for a variety of other metabolites including methionine, S-adenosylmethionine,
FeS clusters, thiamine, and coenzyme A (Mazumder 2016, Mozzarelli 2011).
Although cysteine has universal importance among living organisms, the
biosynthetic routes to cysteine between higher eukaryotes and microorganisms are
distinct. Higher eukaryotic species can either acquire cysteine through the diet or the
transsulfuration pathway, wherein the sulfur group and peptide backbone are derived
from methionine and serine, respectively (Griffith 1987). Prokaryotes, lower eukaryotes,
and plants have a unique biosynthetic route to cysteine that occurs in two steps (Figure
4-1). First O-acetylserine (OALS) is formed from serine by serine acetyltransferase
(SAT). Cysteine synthase A (CysK) then mediates a reaction between OALS and sulfide
to form cysteine (Rabeh 2004). Sulfide, in this case, is derived from the reductive sulfate
assimilation pathway (RSAP) instead of methionine (Sekowska 2000).
The metabolic pathways responsible for cysteine biosynthesis and sulfate
assimilation are tightly regulated by the cellular concentrations of various intermediates
and products of these pathways. In the absence of OALS, CysK is inhibited by the Cterminal tail of the upstream enzyme SAT (Campanini 2005). Furthermore, the CysK
product cysteine inhibits SAT. A high cellular pool of OALS results in the spontaneous
rearrangement of OALS to N-acetyl-L-serine, which induces the sulfate assimilation
pathway (Kredich 1992).
Downstream of cysteine biosynthesis and the RSAP, cysteine acts as a precursor
for homocysteine, which feeds into the methyl cycle and the folate cycle in both
prokaryotes and eukaryotes (Figure 4-1). Methionine synthase produces methionine
from homocysteine and represents a juncture between two metabolically significant
pathways: the methyl cycle and the folate cycle (Ferla 2014). These two pathways have
indispensable roles in protein biosynthesis, DNA biosynthesis and repair, and
methylation reactions.
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Figure 4-1. Cysteine metabolism and related pathways in microorganisms.
SAT = serine acetyl transferase; CysK = cysteine synthase A.
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Cysteine and virulence in pathogenic microbes
In addition to cysteine’s role in protein structure and several fundamental cell
processes, this amino acid also has well-established roles in virulence among several
microbial species. The antioxidant properties of cysteine and its derivatives counteract
redox stress from the host during infection (Bornemann 1997, Mori 2015). S.
typhimurium has heightened susceptibility to certain antibiotics in the absence of the
cysteine biosynthetic operon, and the differentiation of swarm-cells requires cysteine
biosynthesis (Turnbull 2008). RSAP genes in mycobacteria are upregulated in conditions
of oxidative stress and nutrient deprivation, which mimics the conditions encountered
during the latent phase of tuberculosis infection (Hatzois 2011). Cysteine is the primary
low molecular weight antioxidant in various protozoan parasites (Nozaki 2005). In E.
histolytica, cysteine has well-established roles in attachment, proliferation, and motility
(Mori 2015).
Current antibiotic drug discovery efforts towards CysK
The unique biosynthetic route to cysteine among microorganisms as well as the
roles of cysteine and sulfur assimilation in virulence suggests cysteine biosynthesis is a
favorable target for new antimicrobial development. The available literature indicates
drug discovery efforts towards CysK as early as the 1970s (Kredich 1975). Kredich and
coauthors revealed the ability of 1,2,4-triazole to inhibit the growth of S. typhimurium
through interaction with the CysK enzyme. It was demonstrated that several enzymes
within a regulon for the RSAP were downregulated in response to 1,2,4-triazole
treatment. Additionally, it was determined that the CysK enzyme could form a false
product between the triazole and the native CysK substrate OALS. The authors
developed the intriguing hypothesis that rather than inhibiting CysK function directly, the
triazoles contributed to growth inhibition through depleting cellular pools of OALS,
which is necessary for induction of the RSAP pathway (Kredich 1975). These effects
were later confirmed by showing dose-dependent reduction of RSAP genes in response to
1,2,4-triazole treatment in S. typhimurium (Turnbull 2008).
Interest in CysK as an antimicrobial target gained stamina at the turn of the
century. The CysK enzymes of several pathogenic species have been investigated
structurally and evaluated for inhibitor development including E. histolytica (Nagpal
2012, Mori 2015), S. typhimurium (Spyrakis 2013, Magalhães 2018), M. tuberculosis
(Jean Kumar 2013, Poyraz 2013), H. influenzae (Salsi 2010, Amori 2012), and T.
vaginalis (Singh 2013, Westrop 2006). In contrast to the false-product mechanism of
1,2,4-triazole, the majority of the more recently established CysK inhibitor campaigns
generate molecules that directly inhibit the enzyme similarly to the C-terminal tail of
SAT (Campanini 2005, Salsi 2010).
Within this chapter, thioacetamide-linked 1,2,3-triazole (TAT) hits from the
metabolic screen in Chapter 3 are characterized as new antimicrobial agents targeting
CysK in the GN pathogen E. coli. A comprehensive set of experimental approaches are
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employed to confirm the putative target as well as the molecular MOA. These studies
present a novel TAT series with a promising new antimetabolite MOA against clinically
significant strains of GN bacteria.
Materials and Methods
Spontaneous mutant generation and genomic sequencing
ATCC 2511 agar plates were prepared containing each of the three validated hit
compounds at 100 µg/mL. Each of these plates was inoculated with 3x108 CFU of E.
coli K12 MG1655 in 1 mL M9 media, which was spread evenly over the agar and
allowed to dry. The plates were incubated at 37° C. Colonies were apparent but very
faint after 24 hours, so the plates were allowed to incubate another day. By 48 hours,
adequately sized colonies were visible. Five colonies for each hit compound were used
to inoculate M9 containing the respective compounds at 100 µg/mL. The parent E. coli
was also used to inoculate M9 liquid media containing the compounds. Most of the
selected mutants survived and grew in the compound-containing media, while the parent
E. coli did not grow.
A single colony of each mutant was used to inoculate overnight cultures in M9
containing 100 µg/mL of the compound used to generate each mutant. The Qiagen
DNeasy Blood and Tissue Kit was used to extract genomic DNA from each mutant. The
genome sequence of each strain was determined through HiSeq Illumina sequencing.
CLC Genomics Workbench was used to map the resulting reads to the E. coli K12
MG1655 reference genome (GenBank U00096.3) using CLC Genomics Workbench.
Fixed ploidy variant detection was used to determine the spontaneous mutations present.
Susceptibility testing
MIC testing was performed as previously described in Chapter 2.
Structural similarity search based on hit compounds
A nearest neighbor structure search was performed on the entire St. Jude
compound collection with structures from an initially identified set of active compounds,
as queries. The MDL Public Keys (Durant 2002), implemented in Pipeline Pilot (Dassault
Systemes BIOVIA 2018), were used as molecular fingerprints for the nearest neighbor
search. A Tanimoto Coefficient cutoff of 0.8 was used to limit the number of nearest
neighbors identified from the search.
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EcCysK heterologous expression and purification
The CysK construct encoding the cysK gene (UniProt P0ABK5) for heterologous
protein expression and purification was cloned into the NdeI-NheI cloning site of the
pET-28a(+) vector by GenScript. The N-terminal region consisted of a 6X-Histidine tag
with a thrombin cleavage site between the histidine tag and the cysK gene. This plasmid
was transformed into chemocompetent BL21(DE3) E. coli cells. Growth in the presence
of 50 μg/mL Kanamycin, as well as sequencing via the T7 primer set, confirmed
successful transformation of the plasmid and correct sequence of the construct.
A single colony of this host strain was used to inoculate an overnight culture in
LB with Kanamycin. The next day, this culture was diluted 1:100 in 4 liters of
LB/Kan50 and allowed to grow to an OD600 of 0.5. IPTG was added to a final
concentration of 1 mM, and the culture was incubated overnight at 18° C. The bacteria
was then pelleted at 3,700 RCF, 10 minutes, 4° C and the pellets were stored at -20° C for
up to two weeks.
For every liter of bacteria, 50 mL of lysis buffer was prepared. This buffer
consisted of Buffer A (50 mM Tris-HCl, 500 mM NaCl, 5 mM imidazole, pH 8.0), 1
protease pellet (Roche 11-836-170-001), and 450 mg of chicken egg lysozyme. The
pellets were thawed and resuspended by pipetting into this buffer until the bacterial
pellets were in solution. This was followed by sonication at 100% amplitude for 3
minutes followed by a 1-minute rest. The sonication was repeated two more times. The
sonication time was increased by another 3 minutes for every additional liter of bacteria
included.
After the sonication, the lysate was centrifuged at 20,000 RCF, 20 minutes, and 4°
C. The supernatant was retained and filtered through a 0.22 µM filter. The lysate was
then run over two stacked HisTrap HP 5 mL columns at 0.5 mL/minute using the AKTA
Pure purification system. The His-tagged target protein was eluted using a continuous
gradient of 0-100% Buffer B (Same formulation as Buffer A but with an imidazole
concentration of 500 mM) run at 0.5 mL/minute for 2 hours. Fractions with elevated UV
spectra were analyzed by denaturing gel electrophoresis and total protein staining to
ensure purity and correct size of the protein. Fractions that were at least 95% pure were
pooled and ran over a HiPrep 26/60 Sephacryl S-300 HR column at 0.5 mL/minute in 50
mM HEPES, 150 mM NaCl, pH 7.6. The resulting fractions that showed elevated UV
spectra were again analyzed by total protein staining. Fractions containing CysK protein
were pooled, aliquoted and flash frozen. The protein was stored at -80° C until ready for
use.
Spectroscopic studies with CysK
To ensure the PLP cofactor was fully incorporated into the CysK protein, CysK
was allowed to gently rotate with 0.5 mM PLP in 25 mM HEPES, 150 mM NaCl, pH 7.6
for 30 minutes. Since PLP exhibits its own spectroscopic profile, exogenous cofactor
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was removed by then equilibrating CysK into the same buffer lacking PLP by washing
with equivalent volumes three times in a 10,000 MWCO centricon. OALS was prepared
in the same buffer, while all inhibitory molecules were prepared in DMSO. Final assay
concentrations were 100 µM CysK and 500 µM for both substrate and inhibitors. The
DMSO concentration for all samples was 1.25%.
RNA-seq studies
Two medias were used for the RNA-seq analysis. M9 is the standard M9-based
media ATCC2511 used in previous experiments, and M9T has the same media
composition with taurine as the sulfur source. To make M9T, magnesium sulfate was
omitted, and magnesium chloride was added at a final concentration of 2 mM. Taurine
was added at a final concentration of 0.25 mM (Gyaneshwar 2005).
A single colony of E. coli K12 MG1655 was picked into 5 mL M9 broth and
grown overnight at 37°C, 225 RPM shaking. The next day, two 200 µL samples were
taken from the overnight culture and pelleted at 3700xG for 10 minutes. The supernatant
was removed and one sample was washed in 1 mL M9 while another sample was washed
in 1 mL M9T. The samples were pelleted as before and the supernatant removed. The
samples were resuspended in 100 µL of their respective media and added to 100 mL of
M9 or M9T. The cultures were allowed to grow to mid-log at 37°C, 225 RPM shaking.
Five mL of mid-log culture was added to 50 mL conical tubes containing 50 µL DMSO
or 50 µL of 1.56 mg/mL 3866 to achieve a final concentration of 15.6 µg/mL. The
cultures were allowed to drug for 30 minutes at 37°C, 225 RPM shaking. Afterward, 10
mL RNAprotect Bacteria Reagent was immediately added and mixed with the drugged
cultures and pelleted at 5,000xG for 10 minutes. The supernatant was discarded and the
pellets were flash frozen. Each group (drugged and undrugged in either M9 or M9T) was
prepared in triplicate from three different colonies.
For RNA extraction, pellets of E. coli K12 were re-suspended in 100 µL of 1
mg/mL lysozyme and incubated at 37°C for 10 minutes with 5 seconds vortex every 2
minutes. Subsequent steps were carried out using the RNeasy extraction kit (Qiagen)
according to protocol. RNA was eluted in 40-50 µL of supplied elution buffer. Residual
genomic DNA contamination was depleted using RNA Clean and Concentrator kit
(Zymo Research) following the manufacture’s protocol. Samples were eluted in 50 µL of
DNase/Rnase-Free water. Quality of RNA samples was measured using an Agilent 2100
Bioanalyzer and RIN values were all > 7.0.
The ScriptSeq™ v2 RNA-seq Library Preparation Kit was used to prepare the
RNA-seq library. Total RNA was sequenced as 100 bp paired end reads using Illumina
HiSeq technology. Ribosomal RNA sequences were filtered out using BBDuk
{https://jgi.doe.gov/data-and-tools/bbtools/}. The resulting reads were aligned to the
reference E. coli str. K-12 substr. MG1655 genome (NCBI) using Rockhopper
{23716638} to generate the gene counts. Differential gene expression analysis was
analyzed using the DESeq2 analysis package {25516281} in the R statistical computing
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environment from the raw gene count data of the protein coding sequences generated
from Rockhopper.
Results and Discussion
Among the validated hits from the HTS in Chapter 3, three molecules originating
from the Lead-Like library were selected for further lead development and assigned lab
identification numbers. These compounds shared a 2-((1H-1,2,3-triazol-5-yl)thio)-N(phenyl)acetamide scaffold (thioacetamide-linked 1,2,3-triazoles or TATs), and their
growth inhibition was antagonized by methionine (Table 3-2 and Figure 4-2). These
qualities indicated the possibility of a common MOA between the three molecules.
Initial characterization of the TAT hits and target determination
The three Lead-Like hits 3866, 3865, and 3864 were synthesized in-house and
their MICs confirmed. The newly-synthesized compounds maintained growth inhibition
against E. coli K12 and their MIC could still be antagonized by methionine
supplementation (Table 4-1). To obtain preliminary indications towards the target of the
TATs, E. coli spontaneous mutants were raised separately against the three compounds
on M9 agar with inhibitor concentrations equivalent to ~30-60x the MIC. The resulting
resistance frequencies were in the range of 1-3 x 10-7 CFU.
For each compound, five colonies were selected from the spontaneous mutant
plates to screen for cross-resistance to the other hit compounds. All five colonies
selected for 3864 and 3865 were successfully cultivated and maintained resistance. Only
two of the five colonies selected for 3866 continued to grow in the presence of 3866. All
12 mutants were resistant to all three TAT Lead-Like hits, indicating a shared MOA
(Table 4-2).
To investigate the mechanism of resistance to the TAT inhibitors, genomic DNA
was extracted from the twelve spontaneous mutants and sequenced. The strains tested
had nonsynonymous mutations in the cysK gene, which encodes cysteine synthase A
(CysK) (Table 4-3). The nearly universal presence of cysK mutations in the E. coli
spontaneous mutants was a robust initial indication that CysK is targeted by the TATs.
Modeling of observed resistance mutations on the E. coli CysK enzyme
Given the fact that nearly all mutants had nonsynonymous mutations in the CysK
protein, it seemed possible that the lead molecules may interact directly with this enzyme.
CysK is a pyridoxal-L-phosphate (PLP) dependent fold type II enzyme with a substrate
binding channel between the N- and C-terminal domains (Mozzarelli 2011). Within this
channel is an invariant lysine that forms an internal aldimine linkage with PLP, which
switches to an external linkage with OALS as part of its catalytic mechanism. PLP is
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Figure 4-2. Thioacetamide-linked 1,2,3-triazole hits from the metabolic screen.
Original St. Jude numbers and assigned lab identification numbers are shown.

Table 4-1.

Preliminary MICs and resistance frequency of the TAT hits.
E. coli K12
µg/mL MIC90

L-methionine
MIC Shifta

Resistance
Frequencyb

3866

1.6

2

1.3 x 10-7

3865

3.1

2

2.7 x 10-7

3864

3.1

4

2.8 x 10-7

Lee No.

Structure

a

Methionine shift is a ratio of the MIC in the presence of 20 µg/mL L-methionine over
the MIC in M9 with no supplements.
b
Determined in the presence of 100 µg/mL of each compound.
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Table 4-2.

MIC shifts of spontaneous mutants at 24 hours.
3864 Mutant No.

Compound

1

2

3865 Mutant No.

3

4

5

1

2

3

3866 Mutant No.

4

5

1

4

3864

64

64

64

>64

64

64

64

64

64

64

>64

>64

3865

>64

>64

>64

>64

64

>64

>64

>64

>64

64

>64

>64

3866

>64

>64

>64

>64

>64

>64

>64

>64

>64

64

>64

>64

SMX

-

-

-

-

-

-

-

-

-

-

-

-

TMP

-

2

-

-

-

-

-

2

-

2

2

-

CAM

-

-

0.5

-

-

-

-

-

0.5

-

-

0.5

KAN

-

-

-

-

2

-

2

2

-

2

2

-

SMX = Sulfamethoxazole, TMP = Trimethoprim, CAM = Chloramphenicol, KAN =
Kanamycin. Dashes represent the absence of a detectable MIC shift (Mutant MIC/WT
MIC = 1).
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Table 4-3.

Chromosomal mutations in spontaneous E. coli K12 mutants raised against the TATs.
Mutantc

Positiona

Mutation Typeb

Residue
Change

686073

SNV, A→C

ND

gltI

987494

SNV, T→G

ND

asnS

x

1207789

SNV, C→G

ND

tfaE

x

2532518

SNV, C→A

P37H

cysK

x

2532538

SNV, C→G

R44G

cysK

2532616

SNV, A→T

S70C

cysK

2532620

SNV, G→C

G71R

cysK

2533321

SNV, C→A

R305S

cysK

2533322

SNV, G→T

R305L

cysK

2533325

SNV, A→T

Y306F

cysK

Gene

3864-1

3864-2

3864-3 3864-4 3864-5 3865-1 3865-2 3865-3

3865-4

3865-5 3866-1

3866-4

x
x
x
x

x

x
x

x

x

x
x
x

SNV = Single nucleotide variation; ND = Not determined.
a
Position in genome is relative to E. coli K12 MG1655 genome (GenBank: U00096.3).
b
Nucleotide change is shown after mutation type.
c
The letter x indicates presence of mutation.
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restored to the internal aldimine linkage after the addition of sulfide and release of the
cysteine product (Schnell 2007).
To investigate the locations of the spontaneous mutations on CysK, the affected
residues were mapped on a previously solved structure of E. coli CysK (PDB 5J43)
(Figure 4-3). The aminoacrylate intermediate from a structure of M. tuberculosis CysK
(PDB 2Q3D) was overlayed to study the proximity of the mutations to the substrate. All
mutations tracked to the substrate binding channel of CysK (Figure 4-3). Two mutated
residues P37 and R44 are located directly next to the invariant lysine K42 involved in
PLP binding. S70 and G71 are situated in a conserved loop that interacts with the
carboxyl groups of three known ligands of CysK including the SAT C-terminal
isoleucine, the aminoacrylate reaction intermediate, and the benzoic acid moiety of a
thiazolidine inhibitor of M. tuberculosis cysteine synthase (Poyraz 2013). The roles of
R305 and Y306 were less clear from the existing literature, but these residues still track
to the interface between the two subunits of CysK where ligand binding occurs.
Homology of resistance mutations in the CysK enzyme of various species
In order to investigate whether the mutated residues residing within the substrate
binding channel are well conserved, an alignment of the CysK primary sequences from
ten species was assembled (Figure 4-4). In addition to E. coli, the organisms selected
were other GN pathogens as well as various species for which CysK is well studied.
Residues and/or regions previously reported as having established roles in catalysis were
noted (Dharavath 2017). All six residues altered during spontaneous mutant generation
were in sites that were 100% conserved among several GN species, intracellular
parasites, and even the model plant organism Arabidopsis thaliana. Furthermore, all
mutated residues except R305 and Y306 were either directly within or proximal to
regions involved in ligand binding. The location of mutations in highly conserved
regions necessary for substrate interactions suggests the TATs may interfere with the
catalytic function of CysK.
Cellular studies further confirm CysK as the target of lead inhibitors
To further study the role of CysK in growth inhibition by the lead TATs, the E.
coli BW25113 ΔcysK JW2407 strain, as well as the parent strain, was obtained from the
Keio collection (Table 4-4) (Baba 2006). Growth rate studies revealed that the ΔcysK
strain had a severe growth defect in M9 minimal media, which lacks all twenty amino
acids (Figure 4-5A). Supplementation of cysteine to the media restored the growth curve
to a trend very similar to the WT strain, indicating that cysteine starvation is responsible
for the growth defect in the knockout strain. Addition of 3866 to the M9 media at 16
μg/mL (10x the E. coli MIC) inhibited the growth of the WT strain over the 24 hours that
growth was measured, but the addition of cysteine restored WT growth in the presence of
inhibitor (Figure 4-5A). The similarities between the phenotypic effect of inhibitor and
loss of the cysK gene suggests 3866 may act through inhibiting CysK function, resulting
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Figure 4-3. Location of spontaneous mutations on E. coli CysK.
CysK structure is from PDB 5J43. Lysine 42, which is required for binding with the PLP
cofactor, is in green. Residues altered by observed mutations are red and the amino
acrylate intermediate from PDB 2Q3D is represented by pink sticks.
.
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Figure 4-4. Sequence alignment of CysK and location of mutations induced spontaneously for resistance to TATs.
Stars represent location of observed nonsynonymous CysK mutations in spontaneous mutants. The triangle represents the invariant
lysine required for interaction with PLP. Red boxes indicate residues known to interact with the SAT C-terminal tail. Blue boxes
indicate residues involved in PLP interactions. Residues with established roles in interactions with SAT or PLP were identified in
Dharavath 2017.
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Table 4-4.

Strains used for characterization of the TATs.

Strain
E. coli K12 MG1655
E. coli BW25113
E. coli JW2407
BW pPJ131 empty
JW2407 CysK
JW2407 CysKS70C

Characteristics/Genotype
Control for susceptibility testing
Parent of knockout strains
BW25113 ΔtolC, KANR
BW25113, pPJ131:CBNR
BW25113 ΔtolC pPJ131:CysK, KANR. CBNR
BW25113 ΔtolC pPJ131:CysKS70C, KANR, CBNR

Source
ATCC 700926
(2006 Baba)
(2006 Baba)
This study
This study
This study

Note: CBN = Carbenicillin.

Figure 4-5. Cell-based studies to investigate the putative CysK target.
A. Growth curve study of WT and ΔCysK E. coli strains in the presence of 3866 and/or
L-cysteine. B. Dose-response of 3866 among panel of WT and ΔCysK strains harboring
WT and resistant forms of the cysK gene in the constitutive expression vector pPJ131.
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in cysteine starvation.
To further study target specificity, the cysK gene was cloned into the pPJ131
vector for constitutive expression (Yao 2016). An additional variant of the cysK gene
harboring the frequently observed spontaneous mutation S70C was generated in the same
plasmid (Tables 4-3 and 4-4). These two plasmids were transformed into the ΔCysK
strain. The panel of E. coli strains was subject to increasing concentrations of 3866 in
M9 media and allowed to grow overnight, following methods very similar to a traditional
MIC. After 24 hours of growth, the OD600 values were measured (Figure 4-5B).
Cysteine supplementation again rescued E. coli from growth inhibition. The ΔCysK
strain showed scant growth among all concentrations tested, but in the presence of
cysteine showed a growth profile similar to the WT strain, suggesting cysteine
auxotrophy. In the presence of both 3866 and L-cysteine, this knockout strain did not
appear to have WT susceptibility to 3866 in the absence of supplementation. Addition of
the cysKS70C plasmid to the knockout strain showed a similar resistance profile. These
experiments further confirm CysK as the putative TAT target by indicating phenotypic
similarities between 3866 treatment and the absence of the CysK. Specificity is further
confirmed through the observed correlation between reduced 3866 activity and CysK
target modification.
Lead optimization of the TAT series
A structure-activity-relationship (SAR) study was carried out to see if
modifications to the molecular structure of the TATs could improve potency against E.
coli as well as in vitro pharmacokinetic/pharmacodynamic (PK/PD) properties. For this
dissertation, ten molecules in addition to the original three hits were evaluated in terms of
activity against E. coli and in vitro ADME properties (Figure 4-6 and Table 4-5). These
molecules included two previously established CysK-targeted molecules including 1,2,4triazole and a decapeptide representing the last 10 peptides of E. coli SAT (EcP10,
NHTFEYGDGI, UnitProt P0A9D4) (Figure 4-6A). The MIC against E. coli for 1,2,4triazole was high in comparison to the original TAT hits but detectable, while EcP10 had
no detectable activity.
The other eight molecules evaluated within this study are TAT analogs of the
original hit 3866 (Figure 4-6B). These molecules were either synthesized in-house or
identified using a nearest neighbor structure search to obtain molecules that were already
available in the compound library at St. Jude Children’s Research Hospital with similar
molecular structures to the original TAT hits. MIC detection and in vitro PK/PD studies
on the most potent molecules provided valuable information on the SAR of the TAT
series. Modifications to the triazole moiety imparted the highest consequence to potency,
and the 1,2,3-triazoles were generally more potent than the corresponding scaffolds with
a 1,2,4-triazole. Modifications to the thioacetamide linker generally increased the E. coli
MIC, however the phenyl ring could be modified with little consequence to biological
activity. Although none of the analogs were more potent than the original Lead-Like hit
3866, some in vitro pharmacokinetic properties were improved including solubility and
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Figure 4-6. TAT molecules representing the SAR study.
For each molecule, the E. coli K12 MIC90 in M9 is shown. For lead inhibitors, solubility
(Sol.) is shown in µg/mL and in vitro clearance rate (CLINT) is shown in mL/min/Kg. A.
Previously established CysK-targeted molecules. B. Select TAT analogs and their SAR
summary. Blue region is the triazole moiety, which is most crucial for potency. Red
region is the central portion of the molecule which generally showed a reduction in
activity upon modification. The region highlighted in green was amenable to
substitutions and could be modified to improve the in vitro PK/PD profile.
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Table 4-5.

PK/PD Characterization of Lead TATs.

Compound
3864
3865
3866
3900
3868
3867
Carbamazepine
Albendazole
Ranitidine
Verapamil

Solubility
(µg/mL)
19.0 (±1.5 a)
18.5 (±2.3)
16.5 (±0.82)
21.1 (±1.9)
17.1 (±0.62)
20.6 (±3.1)
20.1 (±0.79)
5.3 (±0.22)
27.2 (±0.84)
39.0 (±0.96)

Plasma Protein
Binding (%)
78.8 (±5.8)
86.6 (±1.0)
90.5 (±1.1)
76.9 (±6.6)
88.8 (±1.3)
71.2 (±9.4)
NT
NT
NT
94.2 (±0.13)

Note: NT = Not tested.
a
Values in parenthesis represent standard deviation.
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Metabolic Stability
Plasma Stability
CLint
t1/2 (hr)
t1/2 (hr)
(mL/Min/Kg)
23.0 (±2.1)
3.7 (±0.30)
5.7
36.3 (±5.5)
4.7 (±0.42)
4.4
34.8 (±4.9)
3.0 (±0.22)
7.0
32.1 (±5.4)
3.6 (±0.34)
5.8
35.5 (±4.0)
4.5 (±0.40)
4.6
19.9 (±1.9)
2.7 (±0.21)
7.7
NT
NT
NT
NT
NT
NT
NT
NT
NT
0.36 (±0.0061) 1.5 (±0.088)
14.0

clearance rate in human liver microsomes (Figure 4-6B and Table 4-5).
Antagonism of MIC by metabolites closely related to L-cysteine biosynthesis
CysK is responsible for producing cysteine, which provides the thiol moiety in
methionine and feeds into the methyl cycle (Ferla 2014). This could explain the shift in
MIC observed in the presence of methionine. To further validate CysK as the target
using differential media conditions, the MIC was measured in the presence of additional
metabolites closely related to cysteine biosynthesis. The 1,2,4-triazole molecule was
included in these studies since it is also known to interact with CysK and has a high yet
detectable MIC in E. coli of 50 µg/mL (Kredich 1975) (Table 4-6).
Several metabolites closely linked to CysK biosynthesis antagonized the growth
inhibitory effect of the triazole-based compounds. These metabolites included OALS,
serine, sulfide, and glutathione. A mix of amino acids representing all 20 standard amino
acids with the exception of cysteine, serine, and methionine exhibited a mild shift of twofold. The 1,2,4-triazole molecule exhibited a similar pattern of antagonism, suggesting a
shared antimetabolite mechanism towards CysK (Table 4-6).
TATs potentiate DHPS inhibitors
Antimetabolites such as the antifolate antibiotics are known to exhibit a high
degree of synergy in combination by inhibiting different enzymes within the same
metabolic network simultaneously (Bermingham 2002, Minato 2018). To explore the
potential for partner agents that could show synergy and/or potentiation in combination
with the TAT series, the ΔCysK strain was first tested against a panel of frontline
antibiotics and experimental antifolates. Given the fact that folate and cysteine
biosynthetic pathways feed into common metabolic cycles such as the folate cycle and
methyl cycle, various antifolates were tested against the knockout strain. In addition to
SMX and TMP, the pterin-sulfamethoxazole compound 568 was tested as well as
MAC173979, which is an inhibitor of pABA biosynthesis that is known to potentiate
other antifolates (Zhao 2016, Thiede 2016). The ΔCysK strain did indeed show
hypersusceptibility to all antifolates tested, as well as increased susceptibility to CAM
and a subtle increase in susceptibility to tetracycline (Table 4-7).
To further confirm the potential for synergistic or potentiation effects between the
TATs and the antibiotics that were more potent against the ΔCysK strain, E. coli WT
checkerboard MICs were performed between these antibiotics and the lead TAT 3900.
The SMX and TMP combination was included as a control and displayed the classic
synergy profile commonly observed between these two antifolates (Figure 4-7A).
Unfortunately, none of the combinations with 3900 exhibited synergy. However, the two
DHPS inhibitors tested, 568 and SMX, were potentiated by 3900 (Figure 4-7B, C).
These effects indicate E. coli is more susceptible to DHPS inhibition when the cysteine
biosynthetic pathway is disrupted, which further confirms the associations between the
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Table 4-6.
Susceptibility testing of TATs in the presence of metabolites related to
cysteine biosynthesis.
E. coli BW25113 MIC Shifta
Compound
3866
1,2,4triazole
EcP10
SMX
TMP
AMP

µg/mL
MIC90
0.78

L-Cys

GSH

L-Met

L-Ser

OALS

Na2S

AA-CMSb

pABA

>256

128

2

128

128

8

2

2

50.0

64

32

4

64

64

4

2

2

>200.0
0.10
0.39
0.78

NT
0.5
0.5
2.0

NT
2
1
1.5

NT
8
1.0
2.0

NT
2
0.5
1

NT
2
0.5
1

NT
2
1
2

NT
2
2
2

NT
>256
1
1

SMX = Sulfamethoxazole; TMP = Trimethoprim; AMP = Ampicillin; GSH =
Glutathione.
a
MIC shift is the ratio of averaged MICs from two experiments in supplemented M9 over
unsupplemented M9. Dashes represent the absence of a shift of two-fold or higher.
b
AA-CMS is all twenty standard amino acids except cysteine, methionine, and serine.

Table 4-7.

Susceptibility of E. coli ΔCysK to various antibiotic compounds.

Compound
Ampicillin
3900
Sulfamethoxazole
MAC173979
568
Trimethoprim
Tetracycline
Chloramphenicol

μg/mL MIC90a
BW25113
ΔCysK
0.78
0.78
3.1
50.0
0.098
0.024
25.0
3.1
3.1
0.78
0.39
0.049
0.78
0.39
3.1
0.78

aTested

ΔCysK fold
decrease in MIC
1
0.063
4
8
4
8
2
4

in M9 supplemented with all standard amino acids except cysteine, methionine,
and serine to accommodate the growth of the knockout strain. MIC90s were determined
after 24 hours of growth.
b
ΔCysK fold decrease in MIC was calculated as a ratio of ΔCysK MIC/BW25113 MIC.
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Figure 4-7. 3900 potentiates inhibitors of DHPS.
Fractional inhibitory concentrations (FIC) (MIC of drug A/MIC of drug B) are shown
from three checkerboard MIC experiments. A. SMX x TMP. B. SMX x 3900. C. 568 x
3900. SMX = Sulfamethoxazole; TMP = Trimethoprim.
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folate and cysteine biosynthetic pathways.
TATs maintain activity against antifolate-resistant GN clinical isolates
The lead TAT compounds 3866, 3900, 3868, and 3867 were tested against a
collection of twelve randomly selected GN E. coli and K. pneumoniae clinical isolates
from St. Jude Children’s Research Hospital with varying antifolate resistance profiles
(Table 4-8). These compounds maintained growth inhibitory activity against all strains
except one K. pneumoniae isolate. Relative to the representative lab strains, in most
cases the MIC did not vary more than two-fold. Resistance to either SMX or TMP in
each strain did not correspond with increased resistance to the TATs (Table 4-8). This
indicates that the MICs detected in lab strains are reflective of MICs against clinical
isolates. Furthermore, despite the possibility of interactions with folate biosynthesis
detected in the potentiation studies, the TATs are not susceptible to circulating antifolate
resistance mechanisms.
In vitro interactions of the TATs with the CysK enzyme
CysK is a PLP-dependent enzyme, and therefore this enzyme has a unique
spectroscopic profile based on the state of the PLP cofactor (Campanini 2005).
Spectroscopy has aided other drug discovery campaigns against CysK and could be used
to characterize interactions with our TAT series. The absorbance spectra of the
apoenzyme shows peak absorbance intensity at 410 nm which shifts to peak intensity at
466 nm and shoulder formation at 330nm upon OALS adduct formation (Steiner 2014).
Inhibitory peptides mimicking the C-terminal tail of SAT increase the fluorescence
intensity of CysK at 510 nm upon binding (Campanini 2005, Spyrakis 2013). To
compare CysK interactions between triazole-containing compounds and inhibitory
peptides, the 1,2,4-triazole molecule and EcP10 were included in the spectroscopic
studies as controls in addition to 3866.
The scanning absorbance profile of recombinant E. coli CysK (EcCysK) exhibited
the expected profile of PLP-dependent enzymes with both internal and external aldimine
linkage states of PLP (Figure 4-8A). Addition of OALS shifted the 410 nm peak to 466
nm and increased absorbance of the 330 nm shoulder. Addition of 3866, 1,2,4-triazole,
and EcP10 alone did not cause dramatic changes to the absorbance spectra, however
EcP10 decreased the absorbance at 410nm (Figure 4-8A). The fluorescence intensity
spectrum was also monitored to see if any changes in the 510 nm emission were apparent.
As expected, EcP10 significantly increased the fluorescence intensity at 510 nm while
OALS decreased the fluorescence intensity relative to the apoenzyme (Figure 4-8B). In
contrast to the peptide inhibitor, 3866 and 1,2,4-triazole had a negligible effect on
fluorescence.
Although the TAT 3866 and the 1,2,4-triazole molecule exhibited very little
change to the absorbance and fluorescence spectra of CysK, notable effects were
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Table 4-8.
Lead CysK inhibitors are effective against antifolate-resistant GN
clinical isolates.
Isolate
E. coli
BW25113
EcCI 1
EcCI 2
EcCI 3
EcCI 4
EcCI 5
EcCI 6
K. pneumoniae
ATCC 700603
KpCI 1
KpCI 2
KpCI 3
KpCI 4
KpCI 5
KpCI 6

MIC90 (µg/mL)a
TMP
3866
3900

AMK

SMX

1.0
6.3
5.2
3.1
3.1
3.1
9.4

0.098
>25
0.39
0.78
>25
>25
>25

0.31
>25
0.49
>25
>25
>25
>25

1.6
1.6
3.5
2.7
1.3
3.1
1.6

0.78
1.6
5.2
1.6
1.0
0.78
1.0

>25
0.78
>25
>25
0.65
>25
>25

3.1
0.68
>25
>25
0.78
>25
>25

33
15.6
>100
12.5
12.5
21
25

1.0
1.6
3.5
3.1
1.6
3.1
1.6
50
25
>100
25
25
25
42

AMK = Amikacin; SMX = Sulfamethoxazole; TMP = Trimethoprim.
a
MICs are an average of at least three experiments.
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3868

3867

1.6
1.3
2.0
2.7
1.0
2.6
1.6

1.2
1.3
1.6
3.1
1.3
2.6
1.6

25
12.5
>100
12.5
12.5
16.7
25

25
12.5
>100
12.5
12.5
16.7
12.5

Figure 4-8. Spectroscopic profiling of EcCysK in combination with native
substrate and CysK inhibitors.
The final concentration of the EcCysK enzyme is 100 μM and all ligands were added at
500 μM. A. Scanning absorbance of EcCysK with individual ligands. B. Fluorescence
spectrum of EcCysK with individual ligands. C. Absorbance spectrum of EcCysK with
combinations of OALS substrate and inhibitors. D. Fluorescence spectrum of EcCysK
with combinations of OALS substrate and inhibitors.
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observed in combination with the OALS substrate (Figure 4-8C, D). The combination of
either 1,2,4-triazole or 3866 with OALS resulted in the restoration of both the absorbance
and emission spectra to what was observed with the apoenzyme. Addition of EcP10
resulted in only subtle changes to either the absorbance or fluorescence spectra relative to
the CysK-OALS complex.
The initial spectroscopic studies were carried out with single concentrations of
enzyme, inhibitor, and substrate. Additional experiments revealed that the observed
changes in the absorbance spectra exerted by both OALS binding and the 3866
interaction with the EcCysK-OALS complex are concentration-dependent (Figure 4-9).
This dose dependency confirmed that the abrogation of PLP-OALS aminoacrylate
formation imparted by 3866 is a true effect.
In contrast to EcP10, the spectroscopy studies yielded no evidence of observable
direct binding effects between the triazole inhibitors and CysK in the absence of OALS.
Furthermore, attempts at the thermal melt assay and surface plasmon resonance failed to
show biophysical interactions between TAT molecules and CysK (data not shown). This
implies that the effect of the TAT series is distinct from SAT C-terminal peptidomimetics
which directly inhibit the CysK enzyme (Salsi 2010). The OALS substrate appears to
need to be present for interaction of 3866 and 1,2,4-triazole with the enzyme (Salsi
2010). The absence of spectra indicating an external PLP linkage in the presence of both
OALS and triazole inhibitor could indicate that a false product has been formed and
released from CysK, which is the mechanism proposed to occur with 1,2,4-triazole
(Kredich 1975).
The transcriptional response of 3866-treated E. coli cells
The biosynthetic pathways involved in cysteine biosynthesis, sulfur metabolism,
and the closely related folate cycle and the methyl cycle are highly regulated by both the
products and intermediate metabolites of these pathways. A likely hypothesis is that the
effect of the TAT compounds on CysK will disrupt the cellular pools of associated
metabolites, and therefore may alter normal regulation of the transcription of genes
within these and potentially other metabolic pathways. Results from these studies will
garner further mechanistic insights into the MOA of TATs.
Kredich and coauthors proposed that the growth inhibitory effect of 1,2,4-triazole
on S. typhimurium was due to false product formation between OALS and the triazole. In
addition to cysteine starvation, reduced intracellular pools of OALS, which induces
sulfur-associated metabolic processes, resulted in downregulation of component enzymes
in the RSAP (Kredich 1975). To study whether 3866 disrupted transcription in the RSAP
or other closely associated metabolic pathways, an RNA-seq study was carried out with
E. coli K12 preparations treated with 3866. Two media conditions were used due to the
high sensitivity of RSAP-associated gene transcription to the available sulfur source.
Inorganic sulfate is known to downregulate transcription of this pathway, which may
mask potential effects of the triazole inhibitors on sulfur metabolism (Gyaneshwar 2005).
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Figure 4-9. Dose-dependent spectroscopic effects.
Both OALS substrate and triazole inhibitor 3866 have dose dependent effects on the
scanning absorbance profile of CysK. A. OALS gradient. Apo-CysK is represented by a
bold black line. Bold red line represents highest concentration of OALS at 1 mM, and
other black lines represent intermediate concentrations of OALS. B. Gradient of 3866 on
OALS-CysK complex. Apo-CysK is again represented by bold black line, OALS-CysK
complex with no inhibitor is represented by red line, bold green line represents 3866 and
CysK without OALS, and all other black lines are intermediate concentrations of 3866 on
the OALS-CysK complex.
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In addition to the standard M9 recipe (ATCC 2511) used for previous experiments, which
has magnesium sulfate as a sulfur source, M9T media was used, which is the same media
composition with the exception of taurine representing the sulfur source.
Before studying inhibitor effects, differences in the E. coli transcriptome between
the two media were studied. Relative to M9, genes from the ssu and tau operons were
the most upregulated in M9T (Figure 4-10). The proteins necessary for transport and
sulfur acquisition from aliphatic sulfonates and taurine are encoded by the ssu and tau
operons, respectively. These effects are in agreement with the well-characterized
homeostatic responses in E. coli to available sulfur sources (Gyaneshwar 2005). The ssu
and tau operons are both negatively regulated by adenosine 5’-phosphosulfate (APS),
which is the first RSAP intermediate after the transport of extracellular inorganic sulfate
such as the magnesium sulfate that is present in M9. Both operons are also regulated by
cellular concentrations of OALS, which may decrease upon CysK-mediated false product
formation (Kredich 1975). Therefore, the two media conditions are suitable to study the
potentially varied transcriptional effects associated with E. coli growth inhibition in either
M9 or M9T.
The transcriptional effect of 3866 treatment of E. coli K12 in both M9 and M9T
was examined. The altered genes were evaluated using both volcano plot representation
(Figure 4-11) as well as through pathway analysis of significantly affected genes (Figure
4-12). Criteria for significant transcriptional changes were again defined as a P value ≤
0.01 and a two-fold change in gene transcription.
The most striking transcriptomic effect of 3866 was the marked downregulation
of genes involved in sulfur metabolism in M9T (Figures 4-11A and 4-12A). Sulfur
homeostatic responses are regulated by two major transcription factors, CysB and cbl
(Gyaneshwar 2005). CysB, which is positively controlled by OALS, is the main
regulator of sulfur homeostatic responses and is necessary for transcription of cbl. CysB
regulates the cys, ssu, and tau operons encoding the RSAP, aliphatic sulfonate
metabolism, and alkane sulfonate metabolism, respectively. The cbl transcription factor
positively regulates the ssu and tau operons and is negatively regulated by APS generated
in the RSAP. The expression of cbl was downregulated in response to 3866 along with
the ssu, tau, and cys operons. Since CysB expression was not significantly altered, a
plausible explanation for the downregulation of these genes is a reduced cellular pool of
the CysB co-activator OALS. This would agree with the CysK-mediated false product
mechanism described with 1,2,4-triazole (Kredich 1975). Furthermore, transcriptional
studies in S. typhimurium have shown a similar negative effect of 1,2,4-triazole on the cys
operon (Turnbull 2008).
These major transcriptomic effects on sulfur metabolism were not observed in the
standard M9 media, likely due to the negative effect of APS on gene transcription
associated with sulfur homeostatic responses. However, dysregulation of genes in
pathways linked to the biosynthesis of several amino acids, the shikimate pathway, and
nucleotide biosynthesis was observed in both medias (Figure 4-12). The glycine
cleavage system, which plays a key role in both serine and glycine catabolism and is
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Figure 4-10. Volcano plot of global transcriptional changes in M9-based media
with taurine as a sulfur source compared to magnesium sulfate as the sulfur source.
Dashed lines represent cutoffs for significant fold-change of transcription at 2 and a Pvalue of 0.01. Genes with significant change in expression and P-value are in blue, genes
with significant transcriptional change but a P-value of > 0.01 are in red. Green dots
represent genes with insignificant changes in transcription in terms of both fold-change
and P-value. Grey dots represent genes with a P-value > 0.01 and no significant
transcriptional change.
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Figure 4-11. Volcano plots of transcriptional responses to TAT treatment.
Dashed lines and coloring are similar to Figure 4-10. A. Global transcriptional response
in standard M9 recipe (ATCC 2511) with taurine as the sulfur source. B. Global
transcriptional response in M9 with magnesium sulfate as the sulfur source.
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Figure 4-12. E. coli pathway networks transcriptionally altered by treatment with 3866.
Genes with both a P-value ≤ 0.01 and a log2fold change of ≥ 1 were selected for analysis. Blue and red shading represent
downregulation and upregulation, respectively. A. Pathway analysis in M9T with taurine as the sulfur source. B. Pathway analysis in
M9 with magnesium sulfate as the sulfur source.
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highly interconnected with the folate cycle, was upregulated in M9 in response to 3866
treatment.
Notably, in both conditions metabolic processes associated with aromatic amino
acid biosynthesis and transport were substantially downregulated (Figures 4-11B and 412). The relationship of aromatic amino acid metabolic processes with cysteine
biosynthesis is not as obvious as the sulfur-associated genes, however there are various
biological associations between aromatic amino acid biosynthesis, sulfur metabolism, and
folate biosynthesis. Chorismate is a shared precursor for both pABA and aromatic amino
acids (Dosselaere 2001). The transcription of the folA gene is under the control of TyrR,
which also regulates aromatic amino acid metabolism (Yang 2007). Tryptophan and
cysteine both share serine as a precursor. In combination with the tryptophan
corepressor, TrpR negatively regulates the tryptophan biosynthetic operon as well as
genes encoding various steps of the shikimate and chorismate pathways responsible for
generation of aromatic amino acid precursors. The other two aromatic amino acids
negatively regulate associated pathways, indicating a buildup of aromatic amino acids
could be occurring in response to 3866. Aromatic amino acid biosynthesis in plants is
triggered in response to sulfur starvation, which is hypothesized to be a response to
glutathione depletion to maintain redox homeostasis (Nikiforova 2006). Further
experimentation is required to elucidate the exact relationship between aromatic amino
acid biosynthesis and other aspects of cysteine, folate, and sulfur metabolism. However,
these findings suggest the effects of inhibiting CysK may extend well beyond cysteine
biosynthesis and dysregulate other metabolically significant pathways.
Conclusions and Future Perspectives
Altogether, the data presented in this study provide multiple indications that CysK
is the target of the TAT inhibitors obtained in the HTS in Chapter 3. The phenotype of
3866, which can be reversed by cysteine supplementation, is consistent with the
phenotype observed with the cysteine auxotrophic ΔcysK strain (Figure 4-5A).
Nonsynonymous mutations in cysK were present in the spontaneous mutants (Table 4-3),
and the introduction of the common mutation S70C in E. coli conferred resistance
(Figure 4-5B). Metabolites closely linked to cysteine biosynthesis imparted substantial
antagonism of the growth inhibitory effect of the triazoles (Table 4-6). The 3866
inhibitor also showed in-vitro interactions with the EcCysK-OALS complex through
spectroscopy (Figures 4-8 and 4-9). These findings link the observed MIC activity with
target inhibition in agreement with established postulates for target determination during
the drug discovery process (Silver 2011, Copeland 2005).
An ongoing goal is to confirm the inhibition modality of the TATs against CysK.
Some evidence of a false product mechanism has already been encountered. Various
nitrogen-containing heterocycles are known to interact with CysK from bacteria and
plants via a false-product mechanism (Kredich 1975, Ikegami 1988). The triazole portion
of the TATs is essential for activity and may be the component of the molecule
responsible for false product formation (Figure 4-6). Furthermore, all cell-based and
spectroscopic studies including 1,2,4-triazole indicated this molecule interacts with E.
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coli and the CysK protein in a manner similar to the TAT series, and the interactions with
the enzyme appear distinct from inhibitory peptides (Table 4-6 and Figure 4-8). The
TATs demonstrated the expected transcriptomic effects on sulfur metabolic processes
that are associated with 1,2,4-triazole treatment and OALS depletion (Kredich 1975,
Turnbull 2008) (Figure 4-11B). The shutdown of these genes, which are under the
control of the primary regulator CysB, relies on the depletion of the CysB co-activator
OALS, which would occur if a false product is formed between OALS and 3866. These
data provide evidence toward a MOA through false product formation as described
previously between CysK and 1,2,4-triazole (Kredich 1975).
Further studies are required to confirm a true cellular depletion of OALS as well
as the formation of a false product, which was not directly addressed in this chapter.
Bioanalytical studies are ongoing to investigate this putative false product reaction in
both in vitro CysK-mediated reactions and in 3866-treated E. coli cells. Furthermore,
efforts to optimize crystallization conditions for the recombinant EcCysK enzyme are
also ongoing. Structural information on the molecular interactions of the TAT inhibitors
obtained through X-ray crystallography may elucidate the inhibition modality and
augment SAR efforts towards this inhibitor series.
Inhibition of metabolic targets that are unique to bacteria and central to
fundamental metabolic processes is an exciting avenue for obtaining desperately needed
new antibiotic targets. CysK is one such example of a potential new target that is absent
in humans and situated at an important enzymatic branchpoint between sulfur
assimilation, cysteine biosynthesis, and the methyl cycle. Similar to the antifolates,
which have saved thousands of lives over nearly a century of use in humans, other
antimetabolites could provide essential treatments desperately needed for multi-drug
resistant pathogens.
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CHAPTER 5. EXPLORING THE INTRACELLULAR TARGET
ENGAGEMENT OF ANTIFOLATES IN GRAM-NEGATIVE BACTERIA
Introduction
Molecular methods to explore target engagement in Gram-negative cells
The GN cell physiology presents several challenges to the drug discovery process.
GN permeability, residence time, and efflux susceptibility all factor into the in vivo
efficacy of the molecules of interest, and assessment of these qualities early in the drug
development process is crucial (Silver 2016). A lack of early stage tools to measure
whole cell uptake and target engagement are common roadblocks, especially for GN
bacteria. Biological tools to assess and optimize GN potency early-on could improve the
attrition rates associated with inhibitor series achieving in vivo and even clinical efficacy.
In response to the formidable worldwide issue of AMR GN infections, much
effort has been put forth in recent years towards improving techniques to determine
compound accumulation in GN bacteria. Liquid chromatography-mass spectrometry
(LC-MS) approaches have been optimized to track the accumulation of compounds into
the GN cell (Davis 2014, Zhou 2015). A recent compound accumulation study on 180
diverse molecules indicated that the presence of a primary amine, low globularity,
amphiphilicity, and low rigidity all contribute to improved GN accumulation (Richter
2017). Raman spectroscopy has also proven useful for label-free tracking of GN
compound accumulation (Heidari-Torkabadi 2015).
Although LC-MS and Raman spectroscopy are validated methods to study GN
compound accumulation, they do not show direct indications of target engagement. An
emerging technique employed in mammalian systems is the cellular thermal shift assay
(CETSA), which can simultaneously show evidence of cell entry and target engagement
in the intact cell system (Martinez 2013, Jafari 2014). This technique relies on the basic
principles of the in vitro thermal shift assay, wherein ligand binding often leads to
thermostabilization of the protein target (Waldron 2003). CETSA allows for the study of
this phenomenon in intact cells and prepared lysates, allowing for target interaction to be
studied in a more physiologically relevant context.
To perform CETSA, a cell or lysate preparation originating from the species of
interest is treated with the desired drugs. For cell preparations, a wash step is often
included after drugging to ensure compound that did not penetrate the cells does not
interact with the target during subsequent lysis steps. After drugging, the samples are
subjected to gradient heating, after which a method of determining the drug-induced heatstabilization of the target is employed. A variety of detection methods have been
developed in recent years. The standard method involves removal of aggregated proteins
from the samples, followed by immunodetection of the resulting soluble fractions
(Martinez 2013).
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CETSA takes into account several important biological factors that many in vitro
assays do not including the ability to permeate the cell membrane of the species targeted,
trapping in cellular compartments, modification of the drug in the cell, and the activity in
the physiologically relevant environment of the cytoplasm (Martinez 2013). Since the
methods required to carry out CETSA are amenable to bacterial systems, this technique
could be useful for studying compound entry in GN cells.
Next-generation inhibitor development of antifolates
The FBP is a promising target for the development of next-generation antibiotics,
and recent insights into the structure and function of component enzymes have allowed
for the rational design of next-generation therapeutics (Bermingham 2002). For example,
propargyl-linked antifolates (PLAs) are designed to have high affinity towards resistant
forms of the DHFR enzyme, and structure/function studies have guided the optimization
of this series (Lombardo 2016). These compounds extend further into a hydrophobic
pocket in the DHFR active site than TMP, while gaining additional hydrophobic
interactions through the propargyl linker. This increased engagement may explain the
affinity maintained between different forms of the enzyme and potent MICs observed
against TMP-resistant strains. Various PLA inhibitor series have been generated with
efficacy against both GP and GN pathogens (Reeve 2016, Schocchera 2016).
Similar to the PLAs, the pyridazine series targeting DHPS has also been
optimized using an improved understanding of folate biosynthesis machinery in recent
years. These compounds engage the pterin binding site, which is well conserved and
predicted to be less resistance prone than the flexible loop region where sulfonamides
bind (Lever 1985, Zhao 2012). An unfortunate discrepancy in this series is a lack of
detectable MIC activity despite a high enzyme affinity. This could be due to either poor
bacterial permeation or differences in the molecular mechanism pyridazines exert against
DHPS as compared to sulfonamides.
Major efflux systems in Gram-negative bacteria
Bacteria have evolved efflux mechanisms to efficiently shuttle a variety of
molecules out of the periplasm and cytoplasm. This results in both intrinsic and acquired
resistance among pathogens. Resistance-nodulation-division (RND) efflux pumps are
widespread among several GN species and are often responsible for MDR (Nikaido
2009). To understand the mechanistic basis of efflux, the major efflux machinery of
several GN species has been characterized. RND pumps have three components
including a transporter extending from the cytoplasmic membrane to the periplasm, an
outer-membrane channel, and a membrane fusion protein (Silver 2016). The bestcharacterized RND efflux complex is in E. coli, consisting of the TolC outer membrane
channel, the AcrB inner membrane transporter, and the AcrA fusion protein. E. coli
strains with the tolC gene knocked out lose their intrinsic resistance to a variety of
antibiotic classes, indicated by substantial decreases in MIC values (Tamae 2008).
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Comparison of MICs between tolC knockout strains and parent strains are routinely used
to assess efflux susceptibility during antimicrobial testing.
Improved strategies to develop GN-effective antifolates
Within this chapter, CETSA techniques are adapted to the GN cell system to
study intracellular target engagement and efflux susceptibility of next-generation
antifolates. A panel of E. coli strains is assembled that enables the study of efflux
susceptibility and the effect of target overexpression on the growth inhibitory effects of
antifolates. Episomal expression of FLAG-tagged DHPS and DHFR enables the CETSA
technique by allowing for immunodetection of target proteins. Ligand-induced
thermostabilization is measured after treatment of both prepared lysates and intact cells to
compare engagement with targets in the physiological cytoplasmic environment as well
as in the presence of the intact GN cell membrane system. Important information is
gleaned on the ability of DHPS inhibitors to engage the target within the GN cell as well
as efflux susceptibility of select PLAs. For the pyridazine showing the best intracellular
target engagement through CETSA, effects of this inhibitor on the E. coli transcriptome
are observed.
Materials and Methods
Minimal inhibitory concentration determination
MIC testing was performed as previously described in Chapter 2 and was carried
out in both LB and M9.
Surface plasmon resonance
Poly-His tagged BaDHPS protein was kindly gifted from the laboratory of Dr.
Stephen White. SPR experiments were performed by the Molecular Interaction Analysis
core at St. Jude Children’s Research Hospital. SPR experiments were conducted at 20° C
using a ForteBio Pioneer FE optical biosensor. BaDHPS was immobilized on
polycarboxylate hydrogel-coated gold chips preimmobilized with nitrilotriacetic acid
(HisCap chips; ForteBio). The chip was primed in 10 mM HEPES pH 7.4, 150 mM
NaCl, 50 µM EDTA, 0.005% Tween20 (chelating buffer) and was preconditioned at 10
µL/min with three 60 second injections of wash buffer (10 mM HEPES pH 8.3, 150 mM
NaCl, 350 mM EDTA, 0.05% Tween20) and one 60 second injection of chelating buffer
before being charged with a 60 second injection of 500 µM NiCl2 in chelating buffer.
After priming into the binding buffer (20 mM Tris pH 7.6, 150 mM NaCl, 1 mM TCEP,
0.01% Tween20, 5% DMSO), BaDHPS was injected until ~3600 RU of protein were
captured. One flow cell on the chip was charged with Ni2+ without adding protein to be
used as a reference cell.
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Compounds were prepared in binding buffer at two concentrations (50 and 100
µM for SMX; 25 and 50 µM for 568; 2.5 and 5 µM for 1462, 3893, 3894, 852; and 100
and 200 nM for 1532 and a control DHPS inhibitor 9229). The solutions were injected in
duplicate for each concentration at a flow rate of 100 µL/min using the OneStep Injection
feature, which exploits Taylor dispersion to generate a concentration gradient that
provides a full titration of analyte in a single injection (Quinn 2012a, Quinn 2012b). A
series of buffer-only (blank) injections were included throughout the experiment to
account for instrumental noise. All compounds fully dissociated from the protein
surfaces, eliminating the need for a regeneration step. The data were processed, doublereferenced, solvent corrected and analyzed using the software package Qdat (version
4.3.1.2, ForteBio). Kinetic rate constants and affinities were determined by fitting the
data to a 1:1 interaction model.
Whole cell CETSA
CETSA methods for GN bacteria were adapted from a protocol for CETSA on
mammalian cell preparations (Jafari 2014). A single colony of the strain to be tested was
grown overnight in LB with 100 µg/mL carbenicillin. The overnight culture was subbed
1:100 in LB with no selective agent and grown to a mid-log OD600 between 0.4 and 0.6.
Mid-log bacteria was drugged at a final concentration of 100 µM for the DHPS inhibitors
and 10 μM for the DHFR inhibitors, with a final DMSO concentration of 2%. The
drugged cultures were allowed to shake at 225 RPM, 37°C for 30 minutes, after which
the cells were moved to ice and 300 uL taken from each culture for an OD600 read. The
remaining culture was spun at 4,000 x G for 5 minutes. The supernatant was discarded
and each pellet washed with 2 mL CETSA buffer, which consisted of 20 mM Tris, pH
7.5, 200 mM NaCl with one protease inhibitor (cOmplete mini 11836170001) per 10 mL
of buffer. The cultures were spun as before and supernatant discarded. During the
centrifugation and wash steps, OD600 values were determined and the resuspension
volume calculated. For DHPS, pellets were suspended at 4X the OD600. For DHFR,
pellets were resuspended at 2X the OD600. 30-100 µL was aliquoted into PCR strips, and
the cells were administered an optimized heat gradient using the Veriti Thermal Cycler
for 3 minutes, followed by a 3-minute rest at room temperature. The cells were then
flash-frozen in liquid Nitrogen. The cells were thawed and lysed by adding 5 uL 10
mg/mL lysozyme for every 100 uL cells and incubated at 37°C for 30 minutes. The lysed
cells were pelleted at 20,000xG for 20 minutes at 4°C. 19.5 µL supernatant was collected
from each sample and mixed with 7.5 µL LDS in a 96 well PCR plate. Plates were stored
at -20°C for up to two weeks before immunodetection.
Lysate CETSA
The cells used for the lysate CETSA strains were grown as described for the
whole cell CETSA to a mid-log OD600. The cells were spun and washed in CETSA
buffer as before and resuspended at the CETSA OD600 (4X OD600 for DHPS and 2X
OD600 for DHFR). The cells were then flash-frozen in 1 mL aliquots and stored at -80° C
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until ready to use. The cells were lysed as previously described for the whole cell
CETSA followed by spinning at 20,000 x G, 20 minutes at 4°C. The supernatants were
retained and pooled if multiple tubes were lysed. Drug tubes were prepared by adding 4
µL of either DMSO or 500 µM drug to 1.5 mL tubes. 196 µL lysate was added to each
drug tube so that the final drug concentration was 100 μM for the DHPS inhibitors or 10
µM for the DHFR inhibitors. The tubes were briefly vortexed then taped to the floor of
an incubator shaker and allowed to equilibrate for 30 minutes at 37° C, 225 RPM. After
drugging, the lysate was aliquoted into PCR strips as before. All subsequent methods
including CETSA gradient heating and subsequent processing were performed as
described for the whole cell CETSA, except no flash-freeze or lysis step was included.
Lysate ITDRFCETSA
For DHPS lysate ITDRCETSA, lysates were prepared as previously described.
Drugs were diluted 1:5 starting at 5 mM, then 1 uL drug added to each of 5 tubes. Only
DMSO was added to the remaining tube. 49 µL lysate was added to each tube and
allowed to incubate as before. During the CETSA heating step, all tubes were heated at a
single temperature of 58°C. All subsequent processing followed the methods for the
lysate CETSA.
Western blotting
1.5 µL of 10X DTT was added to each 13.5 µL CETSA sample/LDS mixture and
heated at 70° C for 10 minutes. 10 µL of each sample was loaded onto a NuPage 12%
Bis-Tris 1 mm 15 well gel. 20 ng FLAG-BAP protein (Sigma P7582) and a blank sample
including only LDS and CETSA buffer were included as controls. The gel running
buffer was 1X MES SDS running buffer. The gels were run at 200 V for 1 hour.
Afterwards the gels were transferred using the iBlot 2 system to transfer to a
nitrocellulose membrane. The membranes were each blocked in 5 mL Odyssey TBS
blocking buffer with 10% goat serum for one hour. Two µL of αFLAG primary antibody
(abcam213519) was spiked into the block buffer and incubated overnight at 4°C. The
blots were washed three times for 5, 10, and 15 minutes in TBST, then incubated with
secondary antibody (LI COR IRDYE 800CW 926-32219) at a 1:5000 dilution for one
hour at room temperature. The blots were washed in TBST as before and imaged on an
Odyssey CLx Imaging System.
Band quantification and data analysis
Image Studio Lite Ver 5.2 was used to quantify band density. For standard
CETSA, the first band at the lowest temperature in the heat gradient was set as 100%
relative band intensity (RBI) and the blank control was set as 0% RBI. The RBI of each
band was calculated relative to those controls. The temperature gradient and associated
RBI values were plotted in GraphPad Prism. For the ITDR CETSA values, the
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Boltzmann equation was used to calculate V50 and R2 values. Constraints were set when
necessary to accommodate curve fitting. When replicate values were plotted, the SEM
was represented on the aggregation curves with error bars.
RNA-seq
The RNA-seq study and data analysis, with the exception of the pathway analysis,
was performed as described in Chapter 5 using the E. coli K12 MG1655 strain. Mid-log
bacterial preparations were drugged at final concentrations of 146 µM for 568 and 100
μM for 3893. To compare shared significant transcriptional changes between groups that
were significantly altered, a Venn diagram was generated using Venny (Oliveros 2015).
Results and Discussion
Selection of molecules to test in the GN CETSA model
Various experimental antifolates show minimal or no activity in GN bacterial
assays. Whether this is due to issues with GN permeability and efflux susceptibility has
yet to be determined, so the fate of these molecules in terms of GN entry and intracellular
target engagement was explored by optimizing CETSA in the GN model pathogen E. coli
BW25113. Ten molecules were chosen for this study (Figure 5-1). Seven of these
compounds target DHPS, including an SMX sulfonamide control and 568, which is the
pterin-sulfamethoxazole inhibitor (Zhao 2016). The other five molecules are pyridazine
inhibitors. Three of these inhibitors, 852, 1532, and 1462, are previously established
pyridazines (Lever 1985, Zhao 2012). Two more recently synthesized inhibitors are 3893
and 3894. 3894 has the primary amine predicted to aid in GN entry, and 3893 is its
synthetic precursor (Richter 2017). Although designed to have high affinity for the
DHPS enzyme, none of the five pyridazines have reported biological activity for
unknown reasons.
Additionally, three compounds were chosen to study DHFR in the GN CETSA
model (Figure 5-1). TMP is an established DHFR inhibitor, serving as a control.
UCP1195 and UCP1218 were kindly gifted from the lab of Dr. Dennis Wright at the
University of Connecticut. These compounds are PLAs designed to have a high affinity
for resistant forms of the DHFR enzyme (Lombardo 2016). Varying susceptibility to
efflux was anticipated against the two PLAs, so they were chosen to study in the CETSA
model to see if efflux could be measured.
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Figure 5-1. Established and experimental antifolates selected for the CETSA
study.
The portion of the FBP including the DHPS and DHFR targets is shown.

87

Binding kinetics analysis of DHPS compounds using surface plasmon resonance
Surface plasmon resonance (SPR) has proven to be a reliable in vitro method for
tracking the binding affinity of DHPS inhibitors (Zhao 2012, Hammoudeh 2014). Within
the set of DHPS-targeted molecules chosen for this study, only 1532 had been previously
characterized using this approach (Zhao 2012, Compound 19). SPR was therefore
performed on all selected DHPS compounds in order to compare in vitro target affinities
with the CETSA data.
SPR was carried out with the B. anthracis enzyme. The DHPS enzyme from this
species has shown favorable stability, reliability, and consistency with SPR testing (Zhao
2012). 1532 continued to have nM binding affinity represented by a KD of 17.1 nM and
had the highest affinity and slowest dissociation rate of the entire set (Table 5-1 and
Figure 5-2). 852, 1462, and 3893 all had binding affinity within the nM range, while 568
and 3894 were in the low µM range. SMX did not exhibit any evidence of a binding
profile in this experiment (Table 5-1 and Figure 5-2). Although sulfonamides interact
with DHPS as part of their MOA, this mechanism involves binding within a flexible loop
region to form a false product in the presence of DHPP. Interaction of DHPS with SMX
when the pterin and PPi sites are unoccupied may not result in a strong enough
conformational change to detect this biomolecular interaction using SPR technology. In
contrast to SMX, all other compounds tested bind the pterin binding pocket and were
designed to have strong binding interactions with multiple conserved residues in this site.
Generation of E. coli strains constitutively expressing DHFR and DHPS
The GN representative bacteria E. coli BW25113 was chosen for the GN CETSA
study (Table 5-2). This strain is well characterized and is also the parent strain for the
Keio collection, which allows for comparison with the available knockout strains (Baba
2006). For overexpression and immunodetection of DHFR and DHPS, the pPJ131
constitutive expression vector was kindly gifted from the laboratory of Dr. Charles Rock
(Yao 2016). The folA and folP genes encoding DHFR and DHPS, respectively, were
individually cloned into the plasmid with an N-terminal FLAG tag and a flexible glycine
linker between the tag and the gene. These N-terminal modifications to the expressed
proteins were designed to enable immunodetection of the expressed proteins via western
blotting during CETSA. The plasmids were electrotransformed into both the parent
strain and a tolC knockout strain derived from the Keio knockout strain JW5503 with the
Kanamycin resistance marker removed (ΔtolC Kan-S) (Table 5-2). Both sequencing
and the ability to grow in the presence of the carbenicillin selective agent for pPJ131
confirmed the presence and correct sequence of the plasmids within each strain.
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Table 5-1.
Compound
SMX
568
852
1462
1532
3893
3894

BaDHPS SPR data for DHPS-targeted compounds.
ka (M-1 s-1)
ND
5.84 (± 0.02) x 104
5.13 (± 0.01) x 105
7.82 (± 0.01) x 105
7.44 (± 0.02) x 105
3.48 (± 0.01) x 105
1.69 (± 0.01) x 105

kd (s-1)
ND
1.90 (± 0.01) x 10-1
4.32 (± 0.01) x 10-1
1.87 (± 0.01) x 10-1
1.27 (± 0.01) x 10-2
2.66 (± 0.01) x 10-1
4.24 (± 0.01) x 10-1

Note: ND = not detected.
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KD (nM)
ND
3250 (± 10)
841 (± 1)
239 (± 1)
17.1 (± 0.1)
763 (± 2)
2500 (± 10)

Rmax (RU)
ND
44.2 (± 0.1)
19.3 (± 0.1)
21.5 (± 0.1)
18.2 (± 0.1)
27.4 (± 0.1)
33.5 (± 0.1)

Figure 5-2. SPR sensograms for the DHPS-targeted molecules.
Sensograms are shown for A. SMX, B. 568, C. 852, D. 1462, E. 1532, F. 3893, G. 3894.
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Table 5-2.

Strains used in the GN CETSA study.

E. coli Strain Background
BW25113
BW25113
BW2513
BW25113
ΔtolC Kan-S
ΔtolC Kan-S:pPJ131
ΔtolC Kan-S:folA
ΔtolC Kan-S:folP

Characteristic/Genotype
None (WT)
pPJ131 empty plasmid, CBNR
pPJ131:FLAG:folA, CBNR
pPJ131:FLAG:folP, CBNR
ΔtolC
ΔtolC, pPJ131 empty plasmid, CBNR
ΔtolC, pPJ131:folA, CBNR
ΔtolC , pPJ131:folP, CBNR

Source
2006 Baba
This study
This study
This study
CGSC 14206
This study
This study
This study

CBNR = Carbenicillin resistant; Kan-S = Kanamycin sensitive; CGSC = Coli Genetic
Stock Center.
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Susceptibility profile of the E. coli CETSA panel against established and
experimental antifolates
In E. coli, overexpression of folA has been shown to confer resistance to TMP,
while overexpression of folP does not affect sulfonamide susceptibility. This is due to
the distinct MOAs of the two enzymes (Palmer 2014). TMP directly inhibits DHFR, and
a higher cellular abundance of the target allows more enzyme to be available to perform
the normal metabolic function of reducing dihydrofolate. On the other hand,
sulfonamides have a false product mechanism wherein the inhibitor competes with pABA
to bind at the same site and form a false product with DHPP.
To examine whether overexpression of each enzyme exhibits similar effects and
also determine the sensitivity of each compound to efflux, MICs were determined for the
ten molecules chosen for the GN CETSA study (Figure 5-1). The MIC assays were
carried out in both LB and M9 broth, since CETSA studies would be carried out in LB
while the minimal nutrient environment of M9 prevents the interference of certain
metabolites with detection of growth inhibition (Zlitni 2013). Among the control
antibiotics, all strains harboring the pPJ131 plasmid were resistant to the carbenicillin
selective agent (Tables 5-3 and 5-4). As expected, the ΔtolC Kan-S strains were
hypersusceptible to the novobiocin control compound and showed more moderate
susceptibility increases towards TMP and ciprofloxacin. The SMX MIC was not altered
by overexpression of the folP gene, but overexpression of folA increased the MIC of all
DHFR-targeted compounds in agreement with other studies (Palmer 2014).
Among the experimental DHPS compounds, 568 was the only potent compound
against E. coli (Table 5-3). The only other DHPS-targeted compound with a detectable
MIC was 852, which had a MIC at the highest concentration tested of 200 µM in the
ΔtolC Kan-S strain in M9. The DHFR-targeted inhibitors all appeared susceptible to
efflux, especially the PLAs. This susceptibility testing confirmed the experimental
antifolates are interacting with their target enzymes similarly to established antifolates.
Efflux susceptibility was also confirmed for the two PLAs. The lack of MIC seen with
the pyridazines, which effectively bind DHPS in the SPR assay, indicates issues with cell
permeability and accumulation in the GN cell are possible barriers to growth inhibition.
Optimization of western blotting conditions for CETSA panel
The available commercial antibodies for many proteins in bacteria are scarce in
comparison to what is available for mammalian targets. Antibody generation towards
new targets can be laborious, time-consuming, and expensive. Therefore, the proteins in
this study were episomally expressed in E. coli with a FLAG-tag, allowing for
immunodetection with commercially available αFLAG antibodies (Table 5-2).
Additionally, this allowed the same antibody set to be used for immunodetection of both
targets, reducing variability introduced by using two distinct primary antibodies. The
plasmids were electrotransformed into both E. coli BW25113 and E. coli ΔtolC Kan-S
(JW5503-KanS) to allow for CETSA testing in both efflux-intact and efflux-deficient
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Table 5-3.

MIC80s of E. coli CETSA panel in M9 minimal media (µM).

E. coli Straina
BW25113
BW25113:pPJ131
BW25113:pPJ131:folP
ΔtolC Kan-S

CBN
5.3
>200
>200
1.6

Controls
CPR
0.024
0.012
0.033
0.015

NVB
>200
>200
>200
0.78

SMX
0.52
0.68
0.65
0.26

1532
>200
NT
NT
>200

DHPS targeting
568 1462 3893
1.0
>200 >200
1.6
NT
NT
1.4
NT
NT
1.8
>200 >200

3894
>200
NT
NT
>200

852
>200
NT
NT
200

TMP
1.3
1.0
0.65
0.26

DHFR targeting
UCP1195 UCP1218
4.2
>50
3.1
>50
NT
NT
NT
NT

For compounds with a MIC within the detectable range, data are an average of three independent experiments. CBN = Carbenicillin;
CPR = Ciprofloxacin; NVB = Novobiocin; SMX = Sulfamethoxazole; TMP = Trimethoprim; NT = Not tested.
a
Strains from Table 5-2 that are not represented in this table did not undergo MIC testing in M9 due to poor growth in this media.

Table 5-4.

MIC80s of E. coli CETSA panel in LB media (µM).

E. coli Strain
BW25113
ΔtolC Kan-S
ΔtolC Kan-S pPJ131:folP
ΔtolC Kan-S pPJ131:folA

Controls
CBN
CPR
9.4
0.081
1.6
0.0053
>200
0.0076
>200
0.0061

NVB
83.3
0.34
0.39
0.39

CBN = Carbenicillin; CPR = Ciprofloxacin; NVB = Novobiocin; TMP = Trimethoprim.

93

DHFR targeting
TMP
UCP1195
UCP1218
5.2
6.3
>50
0.39
0.0015
6.3
0.39
0.0015
6.3
6.3
0.20
>6.3

strain backgrounds.
When lysates of the complete CETSA panel were run side by side, a single band
around 20 kDa was detected for both FLAG-DHFR expressing strains, as well as a band
just above 30 kDa for the two FLAG-DHPS expressing strains (Figure 5-3). Neither of
these bands was present either in lysate from the parent strains or in the strains harboring
the empty plasmid. Some background bands were apparent in all strains but were for the
most part consistent among all samples tested.
Establishment of CETSA melting curves for DHFR and DHPS
To obtain the optimal temperature gradient to achieve a CETSA melt curve for E.
coli expressing each protein of interest, CETSA was first tested on a wide heat gradient
ranging from 37° C to 70° Celsius (Figure 5-4). TMP and SMX were included as
controls for DHFR and DHPS, respectively. After drugging, the cells were washed and
subjected to a CETSA heat gradient. The cells were then lysed and aggregated proteins
removed by centrifugation. The resulting lysates were analyzed via αFLAG western
blotting. Relative band intensities were calculated from the resulting bands. Using the
Boltzmann sigmoidal nonlinear regression analysis to fit curves onto the data,
aggregation temperatures (TAGG) could be determined at which 50% stabilization of the
target protein occurred. Using this analysis, TMP stabilized DHFR by 4.5 degrees
(Figure 5-4A). SMX, however, showed negligible thermostabilization of DHPS in this
assay (Figure 5-4B). Similar to the results seen with SPR, this could be due to the nature
of the interaction of sulfonamides with DHPS (Table 5-1 and Figure 5-2). The ability to
generate aggregation curves for both strains as well as the noticeable TMP-induced
thermostabilization of DHFR yielded the first indication that this model can successfully
detect target engagement in the intact GN cell system.
DHPS lysate CETSA reveals antifolate affinity profile
In vitro inhibitor binding assays are optimized for accuracy, reproducibility, and
adequate signal. However, the optimal conditions necessary for quality in vitro data are
often very different from the physiological environment of the target cell milieu, which is
rich in other proteins that can modify both the inhibitor and the target of interest.
Therefore, the observed fate and binding activity of inhibitors can vary vastly between
these two environments.
To explore potential differences in antifolate binding between these two unique
conditions, the lysate CETSA was employed to compare with the in vitro SPR results.
This method involves drugging prepared lysates instead of intact cells, then subjecting
the lysate samples to similar gradient heating, sample preparation, and immunodection
similar to standard CETSA techniques. This allows for ligand-induced
thermostabilization to be studied in the native environment in the absence of cell
membranes, transport machinery, and efflux systems, which can all interfere with the
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Figure 5-3. Western blot of lysates prepared from full CETSA panel and
background strains.
For every lysate sample (lanes 2-10), approximately 50 µg lysate was loaded for all lysate
samples with the exception of the folP samples, which were approximately 100 μg. 1. 5
µL Novex Sharp Pre-stained Protein Ladder 2. 20 ng FLAG-BAP fusion protein control.
3. BW25113 parent strain 4. BW25113 pPJ131 empty plasmid 5. BW25113 pPJ131:folA
6. BW25113 pPJ131:folP 7. ∆tolC Kan-S parent strain 8. ∆tolC KanS pPJ131 empty
plasmid 9. ∆tolC Kan-S pPJ131:folA 10. ∆tolC Kan-S pPJ131:folP.
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Figure 5-4. Preliminary whole cell CETSA covering a broad temperature range.
For panels A and B, aggregation curves are shown along with TAGG values calculated
using the Boltzmann sigmoidal nonlinear regression fit. The fitted curves are represented
by dashed colored lines and a dashed black line represents 50% relative band intensity on
each graph. The data is representative of two technical replicates, and error bars
represent the SEM. A. CETSA curve for E. coli expressing DHFR. B. CETSA curve
for E. coli DHPS. C. Bands from αFLAG immunodetection.
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ability of the inhibitor to engage its target (Silver 2016).
Lysates from E. coli BW25113 and ΔtolC Kan-S strains expressing the folP gene
were prepared and drugged at 100 μM, after which they were subject to a six-point heat
gradient encompassing the aggregation curve of DHPS. A similar pattern of binding
affinity to the in vitro SPR experiments was seen when comparing the resulting lysate
CETSA curves with each DHPS inhibitor (Table 5-1 and Figure 5-5). The CETSA
profiles were very similar between BW25113 and ΔtolC Kan-S. SMX again showed no
thermostabilization of DHPS relative to the DMSO control. 1532 continued to show the
strongest interaction, stabilizing beyond the detectable range for each strain. 1462 also
shifted TAGG values approximately ten degrees for each strain. In contrast to the SPR
results, MANIC showed slightly stronger stabilization than 3893 (Table 5-1). 3894 had
the lowest thermostabilization of all pyridazines tested. The pterin-sulfa 568 showed a
weak yet detectable increase in the DHPS TAGG (Figure 5-5).
The similar affinity profiles between lysates prepared in the BW25113 and the
ΔtolC Kan-S background ensured a homogenous testing environment between the two
genetically distinct strains in the absence of the cell membrane and associated efflux
machinery. Furthermore, the similar affinity profiles observed during SPR testing
ensured in vitro testing is predictive of DHPS binding interactions in a physiological
environment.
The isothermal dose-response fingerprint CETSA (ITDRFCETSA) is a useful
technique to study the effects of drug concentration on target stabilization (Martinez
2013). Lysate or cell preparations are drugged at varying concentrations, followed by
heating at a constant temperature. To study the effect of concentration on antifolate
interactions with E. coli DHPS, ITDRFCETSA was performed on lysate preparations from
both strains expressing FLAG-DHPS at a fixed temperature of 58° Celsius (Figure 5-6).
Using the same curve-fit analysis as for the previous CETSA experiments, an ITDRF
EC50 was determined for each inhibitor, which represents the concentration at which
50% stabilization of DHPS occurred relative to the highest concentration tested.
Regarding dose-dependency in the lysate ITDRFCETSA model, the DHPS
inhibitors had the exact same ranking as for SPR. 1532 again had the highest potency
with the lowest ITDRFCETSA EC50 at 160 nM, and 1462 also had an EC50 in the nM
range. All other compounds had EC50s in the µM range, and SMX continued to not
show binding effects in this model.
The similarities in interactions with the DHPS enzyme in the in vitro SPR assay,
the lysate CETSA, and the ITDRFCETSA model ensured that outcomes from in vitro
methods track expected outcomes from models of target engagement in the native
cytoplasmic environment. The lysate CETSA and ITDRFCETSA methods are therefore
successful initial techniques to study target stabilization and dose-dependency of inhibitor
binding without interference from issues with cell membrane permeability or efflux,
which can be addressed in later experiments.
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Figure 5-5. Lysate DHPS CETSA.
CETSA aggregation curves and calculated aggregation temperatures (TAGG) for prepared
lysates for the BW25113 strain expressing FLAG-DHPS (A) and the ΔtolC Kan-S strain
expressing FLAG-DHPS (B).

Figure 5-6. DHPS lysate ITDRFCETSA.
Lysate ITDRFCETSA of DHPS inhibitors at 58° C. Dose-response curves are
representative of three independent experiments. Error bars represent the SEM. The
αFLAG western blot of the DHPS bands and the EC50s are also shown.
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Addressing permeability issues with pyridazine inhibitors of DHPS
Although deficiencies in cell entry and efflux susceptibility interfere with
detection of target interactions, they ultimately affect in vivo activity and are therefore
undoubtedly very important qualities to assess early-on. Therefore, the CETSA model
was further employed to study the DHPS inhibitors in intact E. coli cells. To explore
target engagement in the GN cell system, whole cell CETSA was performed on DHPS
expressing strains treated with 100 μM of each DHPS inhibitor (Figure 5-7). All DHPS
inhibitors except 3893 only showed slight stabilization of DHPS within the intact cell of
about 2° Celsius. 3893, however, stood out as having superior binding affinity in the
intact cell system showing a ΔTAGG relative to the DMSO group of about 8° Celsius for
each strain. Although it was promising to find a pyridazine with improved cell
permeability relative to previously established compounds, this effect was surprising
considering 3893 is the precursor to 3894, which was designed to have a primary amine
moiety to accommodate GN entry (Richter 2017) (Figure 5-1). The effect of all other
pyridazines showing very little stabilization compared to the lysate experiments suggests
cytoplasmic cell permeability could be the major barrier to target engagement in the
intact GN cell. RND pump-mediated efflux did not appear to affect the DHPS inhibitors,
as the ΔTAGG values were very similar between the BW25113 and ΔtolC Kan-S strains
(Figure 5-7B).
Global transcriptomic effects of antifolates
Although 3893 was discovered as the first pyridazine showing signs of substantial
DHPS stabilization in the intact cell CETSA, this compound still had no MIC in E. coli
(Table 5-3). Although the pyridazines engage the same enzymatic target as
sulfonamides, the MOA is likely distinct. Sulfonamides undergo a false product MOA
while pyridazines inhibit DHPS directly and likely do not form a false product (Zhao
2012, Palmer 2014). The pterin-sulfa conjugates, however, engage both pterin and
sulfonamide/pABA sites simultaneously and have an MIC against E. coli, suggesting that
the DHPS-mediated false product reaction is not essential for growth inhibition, but that
either direct inhibition of DHPS or the false product itself can result in growth inhibition
(Zhao 2016). DHPS is situated in the metabolically significant FBP and disruption of its
normal function may have an associated transcriptomic signature, which may be
dependent on whether native substrates are fluxed into the metabolically useless false
product reaction. Transcriptional changes in several genes responsible for distinct steps
of bacterial metabolism have been characterized for other antifolates (Nixon 2014).
Comparison of the transcriptomic effect between sulfonamides, pterin-sulfas, and
pyridazines may indicate different impacts on bacterial metabolism as well as the MOA
of the inhibitors.
Treatment with 568 and 3893, however, showed interrogation of metabolically
important pathways (Figure 5-8). There was an interesting overlap with the
transcriptomic effect of the CysK inhibitor 3866 with both of these DHPS inhibitors, as
genes involved in cysteine biosynthesis and sulfur metabolism were jointly altered.
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Figure 5-7. Whole cell DHPS CETSA.
CETSA curves are representative of three independent experiments for BW25113 and
two independent experiments for ΔtolC Kan-S. Error bars represent the SEM. A. Intact
cell CETSA curve for BW25113 expressing DHPS. B. Intact cell CETSA curve for ΔtolC
Kan-S expressing DHPS.
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Figure 5-8. Volcano plots of RNA-seq study of E. coli treated with 568 and 3893.
Dashed lines represent the cutoff for a significant change in gene transcription of twofold as well as a P-value of 0.05. Genes with a significant transcriptional change and Pvalue are in blue, genes with a significant change in transcription but a P-value of > 0.01
are in red. Green dots represent genes with insignificant changes in terms of both
transcriptional fold-change and P-value. Grey dots represent genes with a P-value > 0.01
and no significant transcription change. A. Transcriptomic effect of treatment with 146
µM 568, and B. 100 µM 3893.
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Furthermore, 568 treatment resulted in the dysregulation of the aroF, tyrA, and tyrP
genes involved in aromatic amino acid metabolism, which were also affected in response
to 3866 treatment (Figure 4-11B). The downregulation of cbl, ssuE, and several genes
within the cys operon in 3893 was an interesting effect. In fact, 3866 shared more genes
with 3893 than the two DHPS inhibitors, 568 and 3893, share with each other (Figure 59). Half of these genes were involved in sulfur metabolic processes, including the cysK
gene itself. Although further experiments are required to understand this shared
transcriptomic effect, this finding further indicates a shared metabolic effect between
inhibition of both folate and cysteine biosynthesis initially evidenced in Chapter 4.
Assessing susceptibility to efflux with novel DHFR inhibitors
Both PLAs showed sensitivity to efflux, with much lower MICs in the tolC
knockout strains (Table 5-4). TMP also seemed to be sensitive to efflux to a more
modest extent. The whole cell CETSA was performed with these compounds on both the
parent and the ΔtolC Kan-S strains constitutively expressing FLAG-DHFR to see if
susceptibility to efflux could also be observed using the CETSA assay (Figure 5-10).
The ΔTAGG values were compared to see if the presence of the TolC efflux pump subunit
influenced the extent of thermostabilization of each compound in the intact cell. The
ΔTAGG for the ΔtolC Kan-S CETSA was consistently greater in comparison to the parent
strain for all three DHFR-targeted compounds, which agreed with the increased
susceptibility seen in the MIC assays (Table 5-4 and Figure 5-10).
To ensure the increased stabilization in the ΔtolC Kan-S strain was associated
with efflux, the lysate CETSA was performed on both strains. For TMP and UCP1195,
the ΔTAGG values were very similar between lysates prepared from both strains (Figure
5-11). For all compounds tested, the increase in ΔTAGG in the ΔTolC Kan-S strains
relative to the BW25113 strain was larger in the whole cell CETSA than in the lysate
CETSA, indicating the intact efflux machinery in the whole cell preparation has a
detectable effect that is less pronounced in the lysate preparation. In this CETSA model,
UCP1195 seems to be more sensitive to efflux, which is reflective of the dramatic
differences in susceptibility between the parent and TolC knockout strain during MIC
testing (Table 5-4).
Conclusions and Future Perspectives
New inhibitors of GN bacteria are needed now more than ever. Early-stage
inhibitors must be evaluated for qualities that predict in vivo performance as GN
antimicrobials. CETSA shows utility as one of these early-stage tools to readily
determine target engagement in intact GN cells using standard molecular biology
methods. Although CETSA allows the study of target engagement within the intact cell,
it does not provide quantitative information on the concentration of inhibitor
accumulating inside the cell. Following previously established methods (Richter 2017),
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Figure 5-9. Venn diagrams of shared genes transcriptionally altered between
DHPS inhibitors and the CysK inhibitor 3866.
Genes with at least a two-fold change in expression and a P-value of ≤ 0.05 were
compared between the two groups treated with DHPS inhibitors 568 and 3893 with the
group treated with the CysK inhibitor 3866 (Chapter 4). The Venny tool was used to
generate the Venn diagram (Oliveros 2015).
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Figure 5-10. Whole cell DHFR CETSA.
Data are representative of three independent experiments. Error bars represent SEM. A.
Whole cell CETSA profile for BW25113 expressing DHFR. B. Whole cell CETSA
profile for ΔtolC Kan-S expressing DHFR.

Figure 5-11. Lysate DHFR CETSA.
CETSA aggregation curves and calculated TAGG values are shown for lysates
preparations from BW25113 (A) and ΔtolC Kan-S (B).
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orthologous investigations are currently ongoing using liquid chromatography tandem
mass spectrometry to compare E. coli compound accumulation with the observed CETSA
thermostabilization profiles for the compounds studied. This will provide another earlystage tool to understand how the SAR of pyridazines affects accumulation into the cell in
addition to the cellular target engagement profiles obtained through the CETSA
technique.
An important lesson from this study is that target engagement and affinity does
not necessarily correlate with growth inhibition, even within whole cell studies.
UCP1218 stabilized the TAGG of the BW25113 strain by nearly 7° Celsius despite not
having an MIC against this strain at the same concentration used for CETSA drugging
(Table 5-4 and Figure 5-10). SMX did not show signs of biophysical interactions during
both SPR and CETSA assays, yet it maintains a very low MIC. Furthermore, the
pyridazines have nM affinity within the SPR assay, yet there is still no observable MIC.
The DHPS stabilization observed with 3893 in the intact cell CETSA suggests
intracellular target engagement can be improved, but 3893 has a KD approximately 45
times higher than then lead pyridazine 1532. Investigations are ongoing towards creating
pyridazines that are both high potency and cell permeable.
Although pyridazine 3893 was discovered as showing the best intracellular target
engagement of DHPS, further experimentation is required to understand the discrepancy
between target engagement and biological activity. RNA-seq analysis revealed potential
effects on sulfur metabolism that are shared with the CysK inhibitor 3866.
Unfortunately, a major roadblock was the lack of transcriptomic effects seen with SMX
treatment (data not shown). Whether this is due to the media, drug concentration, or if
there simply is not a strong transcriptomic response associated with sulfonamide
treatment is currently being investigated. However, an ongoing effort is to study the
transcriptomic effects of DHPS inhibitors in combination with TMP. Sulfonamides are
nearly always co-prescribed with TMP in the co-trimoxazole combination, and each drug
is much more potent in combination (Bermingham 2002). Therefore, sulfonamides may
have a more widespread and substantial impact on the E. coli transcriptome when an
additional enzyme within the FBP is inhibited.
Within this study, CETSA showed promise as an early stage tool to track
permeability, efflux, and intracellular target engagement in the GN cell. The standard
methods required for CETSA with an immunodetection readout were amenable to the
bacterial system. The use of a constitutive expression vector expressing FLAG-tagged
target proteins accommodated immunodetection using commercially available antibodies
and a single western blot protocol for both proteins. Stabilization by both established and
experimental antifolates could be detected in both the standard CETSA and the
ITDRFCETSA. CETSA is therefore a useful early stage tool to characterize the activity of
antimicrobial candidates in the GN intact cell system.
CETSA also holds much potential for medium- and high-throughput screening for
antimicrobial compounds using alternative detection modalities to the traditional western
blot. Time-resolved fluorescence resonance energy transfer (TR-FRET) and the
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AlphaScreen rely on antibodies and/or affinity reagents that specifically recognize
properly folded proteins, which eliminates the need for separating soluble from
aggregated components of the lysates (Jafari 2014). Furthermore, various reporter-based
readouts that do not rely on antibodies have been recently developed for CETSA to
eliminate the intensive optimization required for immunodetection (McNulty 2018,
Martinez 2018). These developments inspire much promise towards using CETSA to
address crucial qualities of antibacterial agents during both screening and lead
development stages.
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CHAPTER 6.

CONTRIBUTIONS TO THE FIELD AND LOOKING FORWARD

This dissertation aims to improve the field of antimicrobial discovery from three
major angles, including improved understanding of resistance mechanisms to guide
inhibitor development, the discovery of new antimicrobials disrupting bacterial
metabolism, and improvement of methods to gauge the fate of inhibitors in the GN cell
system. All three are studied in the context of bacterial metabolism.
Improvements to the understanding of sulfonamide resistance mechanisms were
presented in Chapter 2, which guides the development of new DHPS inhibitors that are
impervious to circulating resistance mechanisms. Reported variations in the amino acid
sequence of DHPS among antifolate-resistant S. aureus strains were used to investigate
the basis of sulfonamide resistance in this clinically important pathogen. Unexpected
roles in resistance among secondary mutations were revealed, and nearly all of the
mutations studied had an apparent effect on regions extending beyond the substrate
envelope, which appears most vulnerable to mutation. This has guided the focus of
DHPS inhibitor development to avoid engaging these areas of the enzyme. Most of these
mutations are shared among other pathogenic species, so this information benefits
inhibitor design towards a range of clinically significant pathogens.
Another aim of this dissertation is to improve methods used in early-stage
antibiotic drug discovery, which are addressed in Chapters 3 and 5. During the drug
discovery process, standard biological testing conditions select for a limited number of
bacterial targets. Conventional testing media is often nutrient rich to ensure fast and
optimal growth of the organisms studied, however nutrients within the testing media can
mask the inhibitory effect of various antimetabolites. Therefore, many antimetabolite
inhibitors and new metabolic targets have likely gone undetected in previous HTS
campaigns. In Chapter 3, it was discovered that nutrient-restricted broth is required for
measurement of the biological activity among next-generation antifolates, and
supplementation with metabolites related to the target pathway increased the MIC.
Testing in both nutrient-restricted and supplemented conditions was an effective strategy
both for the detection of biological activity and to ensure an antimetabolite MOA. These
methods were adapted to an E. coli whole cell screen for new antimetabolite compounds,
leading to the discovery of several exciting candidate molecules for drug repurposing as
well as small molecule inhibitors yet to be characterized as antimicrobials. Targeted
whole cell screening in selective media followed by MOA determination is gaining
stamina in recent years due to the wider range of targets discovered along with first-inclass inhibitors that are already whole-cell effective. Ultimately these approaches will
hopefully yield first-in-class antimetabolite inhibitors that will bolster the current
antibiotic armamentarium.
Improvement of antibiotic discovery methods is also addressed in Chapter 5 with
a focus on developing strategies to track the fate of inhibitors in the GN cell system,
which is notoriously difficult to drug. The CETSA technique was adapted to explore
important antimicrobial qualities in this cell system including target engagement in the
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intact cell and efflux. The use of CETSA as an early stage tool for antibiotic discovery is
not as developed as for targets in the eukaryotic cell system, but the methods are
amenable to either cell type. The CETSA methods were adapted to the E. coli cell
system and were used to characterize inhibitors of both DHPS and DHFR within the
FBP. This analysis allowed for the discovery of 3893 as having the best engagement of
DHPS in the intact GN cell system. Furthermore, DHFR inhibitors showed increased
stabilization of the intracellular target in an E. coli ΔtolC strain, which confirmed their
susceptibility to efflux. The CETSA method continues to serve as an early stage tool to
quickly gauge performance in whole cells among new inhibitors. This method has the
potential to greatly benefit other drug discovery campaigns as new classes of GNeffective antibiotics are desperately needed.
The final contribution of this dissertation to the field of AMR is the discovery of a
new series of E. coli inhibitors targeting CysK. The current antibiotic arsenal generally
targets a limited set of cell processes, and cysteine biosynthesis represents a new target
that is absent in humans and positioned at the juncture of multiple metabolic pathways.
The TAT series was discovered in the HTS from Chapter 3 and further characterized in
Chapter 4. Microbial metabolism has garnered interest in recent years among the
antibiotic drug discovery community, and the TAT target CysK has been evaluated for
inhibitor development among several pathogenic species. Similar to the historically
successful antifolate antibiotics, which take advantage of a metabolic pathway unique to
prokaryotes and lower eukaryotes, targeting other metabolic branches such as cysteine
biosynthesis is a promising strategy for acquiring new inhibitors. In contrast to current
inhibitor campaigns towards CysK, the mechanism of the TATs could likely occur
through formation of a false product, which is analogous to the MOA of sulfonamides.
In addition to interfering with the native function of the protein target, false product
mechanisms can alter the available pools of related metabolites and disrupt regulatory
processes. The TATs were found to have a widespread impact on the transcription of
genes in several metabolic pathways beyond cysteine biosynthesis. Altogether, the
unique antimetabolite MOA of the TATs, as well as the widespread impact on E. coli
metabolism, yields much promise towards using small molecules to inhibit GN
pathogens.
The insights garnered from this study will aid ongoing antibiotic discovery
campaigns and foster interest in pursuing microbial metabolism for new inhibitor
development. This dissertation revealed the exciting potential of bacterial metabolism as
a rich source of new and effective antibiotic targets. During the study of metabolic
targets for the development of novel and next-generation inhibitor series, a significant
focus within this dissertation is maintained on shifting conventional paradigms in the
drug discovery field that limit discovery and neglect key properties of candidate
inhibitors that are critical for in vivo efficacy. Although the current AMR crisis is
foreboding, advances outlined in this dissertation towards antibacterial drug discovery
within new metabolic pathways show much promise towards fighting drug-resistant
infections.
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